

CITATION REPORT

List of articles citing

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

DOI: 10.1016/j.cell.2020.05.015
Cell, 2020, 181, 1489-1501.e15.

Source: <https://exaly.com/paper-pdf/84390558/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2238	Global Epidemiology. 1962 , 1, 332-332		
2237	Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. 2020 , 11, 552909		136
2236	Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19. 2020 , 8, 565278		28
2235	Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. 2020 , 10, 1777		14
2234	Survey of Decentralized Solutions with Mobile Devices for User Location Tracking, Proximity Detection, and Contact Tracing in the COVID-19 Era. 2020 , 5, 87		32
2233	Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death. 2020 , 8,		14
2232	Tackling COVID19 by Exploiting Pre-existing Cross-Reacting Spike-Specific Immunity. 2020 , 28, 2314-2315		6
2231	Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. 2020 , 68, 310-313		99
2230	Immunotherapeutic approaches to curtail COVID-19. 2020 , 88, 106924		29
2229	Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?. 2020 , 41, 851-853		5
2228	COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. 2020 , 98, 1559-1567		60
2227	What could explain the late emergence of COVID-19 in Africa?. 2020 , 38, 100760		20
2226	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. 2020 , 77, 168-184		6
2225	High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreak. 2020 , 59, 1475-1484		11
2224	Prospects for a safe COVID-19 vaccine. 2020 , 12,		99
2223	Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?. 2020 , 11, 567710		30
2222	COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes. 2020 , 8, 593455		13

2221	Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. 2020 , 50, 2013-2024		35
2220	[Clinical and epidemiological characteristics of COVID-19]. 2020 , 59, 24-26		
2219	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020 , 183, 169-184.e13	56.2	221
2218	Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. <i>Cell</i> , 2020 , 183, 4-10	56.2	23
2217	SARS-CoV-2 infections in children and young people. 2020 , 220, 108588		51
2216	On the genetics and immunopathogenesis of COVID-19. 2020 , 220, 108591		22
2215	Temporal and age distributions of SARS-CoV-2 and other coronaviruses, southeastern France. 2020 , 101, 121-125		3
2214	Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. 2020 , 1, 100078		92
2213	SARS-CoV-2 infection in India bucks the trend: Trained innate immunity?. 2021 , 33, e23504		8
2212	What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?. 2020 , 6, 100076		38
2211	S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. 2020 , 11,		113
2210	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 2020 , 370,		289
2209	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016		10
2208	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020 , 183, 1024-1042.e21	56.2	601
2207	Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review. 2020 , 76, 1777-1794		26
2206	Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. 2020 , 11, 583252		8
2205	Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients. 2020 , 5,		21
2204	Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19. 2020 , 372, 113410		29

2203	Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. 2020 , 11,	27
2202	Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection. 2020 , 40, 39	24
2201	Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. 2020 , 50, 2025-2040	111
2200	The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. 2020 , 6, 73	87
2199	Spotlight on COVID-19: from biology to therapy and prevention. 2020 , 287, 3606-3608	1
2198	Susceptibility to severe COVID-19. 2020 , 370, 404-405	22
2197	Virology, transmission, and pathogenesis of SARS-CoV-2. 2020 , 371, m3862	271
2196	[Adaptive immunity against SARS-CoV-2]. 2020 , 36, 908-913	2
2195	Global perspective of COVID-19 epidemiology for a full-cycle pandemic. 2020 , 50, e13423	65
2194	BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis. 2020 , 38, 6352-6356	25
2193	Interferon- γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. 2021 , 73, e3130-e3132	52
2192	A systematic review of SARS-CoV-2 vaccine candidates. 2020 , 5, 237	257
2191	Variation and multilevel selection of SARS-CoV-2. 2020 , 74, 2429-2434	3
2190	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. 2020 , 396, 1595-1606	342
2189	SARS-CoV-2 vaccines in development. 2020 , 586, 516-527	961
2188	Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. 2020 , 8, 684-694	48
2187	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. 2020 , 2, 1-23	45
2186	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. 2020 , 41, 1100-1115	345

2185	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. 2020 , 14, 746-751	42
2184	Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. 2020 , 169, 112643	17
2183	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. <i>Cell</i> , 2020 , 183, 996-1012.e19	56.2 711
2182	Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19. <i>Cell</i> , 2020 , 183, 1340-1353.e16	56.2 205
2181	Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. 2020 , 53, 487-495	73
2180	Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. 2020 , 1, 100092	77
2179	SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity. 2020 , 5, 224	8
2178	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. 2020 , 20, 709-713	132
2177	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. 2020 , 117, 25254-25262	116
2176	Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines. 2020 , 19, 781-784	
2175	An -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. 2020 , 12,	96
2174	Global Seasonality of Human Seasonal Coronaviruses: A Clue for Postpandemic Circulating Season of Severe Acute Respiratory Syndrome Coronavirus 2?. 2020 , 222, 1090-1097	45
2173	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. 2020 , 15, 359-386	199
2172	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. 2020 , 26, 1428-1434	223
2171	Lessening COVID-19 healthcare burden in dental practice via rapid serological tests. 2020 ,	1
2170	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. 2020 , 369,	744
2169	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. 2020 , 257, 118058	9
2168	SARS-CoV-2/COVID-19: a primer for cardiologists. 2020 , 28, 366-383	9

2167	Lessons for COVID-19 Immunity from Other Coronavirus Infections. 2020 , 53, 248-263	180
2166	COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. 2020 , 202, 149-161	116
2165	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. <i>Cell</i> , 2020 , 182, 843-854.e12	56.2 185
2164	SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. 2020 , 5,	161
2163	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. 2020 , 396, 467-478	1274
2162	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. 2020 , 396, 479-488	661
2161	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. 2021 , 27, 2126-2136	16
2160	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a. 2020 , 28, 2691-2702	9
2159	Serological follow-up of SARS-CoV-2 asymptomatic subjects. 2020 , 10, 20048	39
2158	The known unknowns of T cell immunity to COVID-19. 2020 , 5,	60
2157	SARS-CoV-2 Proteins Induce in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors. 2020 , 8,	7
2156	Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports. 2020 , 17, 2974-2986	9
2155	HCoV- and SARS-CoV-2 Cross-Reactive T Cells in COVID Patients. 2020 , 11, 607918	19
2154	The immunology of SARS-CoV-2 infections and vaccines. 2020 , 50, 101422	41
2153	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. 2021 , 72, e1130-e1143	14
2152	COVID-19 and lombardy: TESTING the impact of the first wave of the pandemic. 2020 , 61, 103069	25
2151	Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project). 2020 , 9, 262	13
2150	Phenotyping of Adaptive Immune Responses in Inflammatory Diseases. 2020 , 11, 604464	3

2149	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. 2020 , 53, 1281-1295.e5	146
2148	Structure-Based Modeling of SARS-CoV-2 Peptide/HLA-A02 Antigens.. 2020 , 2, 553478	6
2147	Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. 2020 , 53, 1315-1330.e9	99
2146	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. 2020 , 53, 1296-1314.e9	109
2145	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. 2020 , 2,	3
2144	Is Immunological Memory a Burden in Times of COVID-19?. 2020 , 41, 855	1
2143	Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. 2020 , 7, 592629	27
2142	Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic. 2020 , 11, 578382	20
2141	SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. 2020 , 53, 1245-1257.e5	96
2140	Modeling the second wave of COVID-19 infections in France and Italy via a stochastic SEIR model. 2020 , 30, 111101	36
2139	SARS coronavirus 2: from genome to infectome. 2020 , 21, 318	30
2138	Class I HLA Allele Predicted Restricted Antigenic Coverages for Spike and Nucleocapsid Proteins Are Associated With Deaths Related to COVID-19. 2020 , 11, 565730	10
2137	Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?. 2020 , 8,	35
2136	Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India. 2020 , 11, 1339-1344	11
2135	Asynchronous actions of immune responses in COVID-19 patients. 2020 , 5, 284	2
2134	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. 2020 , 11, 6121	36
2133	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An Analysis. 2020 , 2020, 8893483	14
2132	Low-Avidity CD4 T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. 2020 , 53, 1258-1271.e5	119

2131	Characteristics of SARS-CoV-2-specific cytotoxic T cells revealed by single-cell immune profiling of longitudinal COVID-19 blood samples. 2020 , 5, 285	2
2130	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. 2020 , 11, 588409	11
2129	The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein. 2020 , 33, 108454	12
2128	Efforts at COVID-19 Vaccine Development: Challenges and Successes. 2020 , 8,	47
2127	The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. 2020 , 11,	11
2126	Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019. 2020 , 11, 589438	9
2125	Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. 2020 , 11, 583019	38
2124	The role for the metagenome in the pathogenesis of COVID-19. 2020 , 61, 103019	9
2123	The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). 2020 , 10, 19630	85
2122	SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity. 2020 , 9,	2
2121	Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. 2020 , 9, e1204	24
2120	Impact of COVID-19 in Minas Gerais, Brazil: Excess deaths, sub-notified cases, geographic and ethnic distribution. 2021 , 68, 2521-2530	4
2119	Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. 2020 , 5,	32
2118	Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. 2020 , 11, 579220	58
2117	Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden. 2020 , 125, 305-310	19
2116	Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. 2020 , 53, 864-877.e5	264
2115	High incidence of false-positive results of IgG antibody against SARS-CoV-2 with rapid immunochromatographic antibody test due to human common cold coronavirus infection. 2020 , 31, 101180	10
2114	Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients. 2020 , 40, 618-624	30

2113	Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. 2020 , 1, e151	25
2112	Approaches and Challenges in SARS-CoV-2 Vaccine Development. 2020 , 28, 364-370	64
2111	A systematic review of re-detectable positive virus nucleic acid among COVID-19 patients in recovery phase. 2020 , 85, 104494	14
2110	Severe acute respiratory syndrome coronavirus 2, original antigenic sin, and antibody-dependent enhancement: mħage ^trois. 2020 , 32, 458-461	1
2109	COVID-19 in Africa: Dampening the storm?. 2020 , 369, 624-626	94
2108	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. 2020 , 11, 1949	163
2107	Winter Is Coming: A Southern Hemisphere Perspective of the Environmental Drivers of SARS-CoV-2 and the Potential Seasonality of COVID-19. 2020 , 17,	55
2106	The importance of cell-mediated immunity in COVID-19 - An opinion. 2020 , 143, 110152	8
2105	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. 2020 , 584, 353-363	289
2104	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. 2020 , 13,	47
2103	COVID-19: Mechanisms of Vaccination and Immunity. 2020 , 8,	43
2102	Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development. 2020 , 8,	11
2101	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. 2020 , 11, 1817	104
2100	Deciphering the TCR Repertoire to Solve the COVID-19 Mystery. 2020 , 41, 518-530	30
2099	Repurposing CD8 T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?. 2020 , 9, 1794424	5
2098	Interplay between SARS-CoV-2 and the type I interferon response. 2020 , 16, e1008737	244
2097	Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions. 2020 , 11, 131-144.e6	26
2096	T cell responses in patients with COVID-19. 2020 , 20, 529-536	416

2095	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. 2020 , 383, 1544-1555	612
2094	Cellular immune responses to covid-19. 2020 , 370, m3018	29
2093	SARS-CoV-2 Vaccine Development: Current Status. 2020 , 95, 2172-2188	61
2092	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. 2020 , 41, 815-829	66
2091	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. 2020 , 5, 69	86
2090	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020 , 182, 1419-1440.e236.2	558
2089	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. 2020 , 28, 465-474.e4	106
2088	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. 2020 , 584, 437-442	1167
2087	A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations. 2020 , 10, 12512	7
2086	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. 2020 , 370, 89-94	593
2085	Single Virus Targeting Multiple Organs: What We Know and Where We Are Heading?. 2020 , 7, 370	20
2084	Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. 2020 , 369, 1210-1220	485
2083	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. 2020 , 8,	12
2082	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. 2020 , 8,	5
2081	Ten key points about COVID-19 in children: The shadows on the wall. 2020 , 55, 2576-2586	11
2080	SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. 2020 , 584, 457-462	1002
2079	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. 2020 , 12,	52
2078	Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings. 2020 , 20, 1351-1352	9

2077	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020 , 183, 158-168.e14	56.2	955
2076	Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. 2020 , 20, 3149-3161		33
2075	Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. 2020 , 12,		25
2074	Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. 2020 , 5, 156		82
2073	Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. 2020 , 12, 70		51
2072	Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. 2020 , 99, 437-440		46
2071	A Longitudinal Study of Immune Cells in Severe COVID-19 Patients. 2020 , 11, 580250		31
2070	The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. 2020 , 26, 1819-1824		19
2069	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. 2020 , 11, 580987		21
2068	Identification and Characterization of CD4 T Cell Epitopes after Shingrix Vaccination. 2020 , 94,		4
2067	Is Herd Immunity Against SARS-CoV-2 a Silver Lining?. 2020 , 11, 586781		21
2066	Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions. 2020 , 29, e184		11
2065	Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets. 2020 , 11, 587615		36
2064	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980		20
2063	Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. 2020 , 229, 521-524		9
2062	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. 2020 , 11, 921		52
2061	COVID-19 in health-care workers: lessons from SARS and MERS epidemics and perspectives for chemoprophylaxis and vaccines. 2020 , 19, 937-947		7
2060	COVID-19-Lessons Learned and Questions Remaining. 2021 , 72, 2225-2240		34

2059	SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. 2020 , 136, 2905-2917	61
2058	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. 2020 , 6,	66
2057	Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines. 2020 , 11, 586984	44
2056	Immune Correlates of COVID-19 Control. 2020 , 11, 569611	10
2055	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. 2020 , 11, 576622	137
2054	An Effective COVID-19 Vaccine Needs to Engage T Cells. 2020 , 11, 581807	38
2053	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. 2020 , 11, 585354	189
2052	CoVaccine HT α Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. 2020 , 11, 599587	13
2051	Survey of the current status of subclinical coronavirus disease 2019 (COVID-19). 2020 , 26, 1294-1300	10
2050	Identification of a dominant CD8 CTL epitope in the SARS-associated coronavirus 2 spike protein. 2020 , 38, 7697-7701	5
2049	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. 2020 , 10, 200160	116
2048	Unbiased Screens Show CD8 T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. 2020 , 53, 1095-1107.e3	131
2047	Host genetic factors and susceptibility to SARS-CoV-2 infection. 2020 , 32, e23497	3
2046	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. 2020 , 16, 2980-2991	16
2045	Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. 2020 , 117, 24620-24626	59
2044	Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. 2020 , 5,	28
2043	SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. 2020 , 52, 801-808	40
2042	Immunological considerations for COVID-19 vaccine strategies. 2020 , 20, 615-632	480

2041	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. 2020 , 21, 1336-1345	615
2040	Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns. 2020 , 205, 2342-2350	44
2039	Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. 2020 , 46, 102472	52
2038	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. 2020 , 205, 2566-2575	9
2037	Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. 2020 , 136, 2290-2295	147
2036	Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. 2020 , 12,	166
2035	Impaired Cytotoxic CD8 T Cell Response in Elderly COVID-19 Patients. 2020 , 11,	46
2034	COVID-19 healthcare demand and mortality in Sweden in response to non-pharmaceutical mitigation and suppression scenarios. 2020 , 49, 1443-1453	26
2033	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". 2020 , 11, 2059	11
2032	Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases. 2020 , 19, 4398-4406	9
2031	Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19. 2020 , 95, 1448-1451	4
2030	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. 2020 , 5,	105
2029	Coronavirus disease 2019 population-based prevalence, risk factors, hospitalization, and fatality rates in southern Brazil. 2020 , 100, 402-410	6
2028	SARS-CoV-2 Vaccine Development: An Overview and Perspectives. 2020 , 3, 844-858	20
2027	Vaccine against COVID-19 or against SARS-CoV-2 infection?. 2020 , 7, 131-145	2
2026	Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. 2020 , 370, 811-818	121
2025	Not just antibodies: B cells and T cells mediate immunity to COVID-19. 2020 , 20, 581-582	124
2024	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. 2020 , 12,	49

2023	Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome. 2020 , 10, 14179	46
2022	Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. 2020 , 21, e13128	427
2021	Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. 2021 , 73, e2946-e2951	450
2020	Immune responses during COVID-19 infection. 2020 , 9, 1807836	49
2019	The Immune Response and Immunopathology of COVID-19. 2020 , 11, 2037	61
2018	Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. 2020 , 146, 790-798	109
2017	Monocyte activation in systemic Covid-19 infection: Assay and rationale. 2020 , 59, 102964	44
2016	Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?. 2020 , 9,	0
2015	Computational Immune Proteomics Approach to Target COVID-19. 2020 , 19, 4233-4241	12
2014	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. 2020 , 383, 1168-1180	6
2013	Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses. 2021 , 73, 554-555	8
2012	Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program. 2020 , 60, 2938-2951	36
2011	Covid-19: Do many people have pre-existing immunity?. 2020 , 370, m3563	48
2010	Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. 2020 , 324, 1781-1782	96
2009	Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines. 2020 , 15, 572-573	8
2008	Vaccines for COVID-19. 2020 , 202, 162-192	93
2007	SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. 2020 , 72, 2313-2330	7
2006	The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector. 2020 , 54, 1-15	11

2005	Severity of Coronavirus Disease 2019 (COVID-19): Does Surfactant Matter?. 2020 , 11, 1905	7
2004	T cells in COVID-19 - united in diversity. 2020 , 21, 1307-1308	31
2003	Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins. 2020 , 12, 1247-1255	18
2002	Thoughts From the Trenches: Should We Look at the "Healthy"?. 2020 , 8, 490	
2001	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. 2020 , 12,	9
2000	Villitis of Unknown Etiology in the Placenta of a Pregnancy Complicated by COVID-19. 2021 , 37, 167-171	2
1999	COVID-19 and the Path to Immunity. 2020 , 324, 1279-1281	99
1998	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). 2020 , 21,	16
1997	Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein. 2020 , 5, 81	11
1996	Suboptimal SARS-CoV-2-specific CD8 T cell response associated with the prominent HLA-A*02:01 phenotype. 2020 , 117, 24384-24391	92
1995	A dynamic COVID-19 immune signature includes associations with poor prognosis. 2020 , 26, 1623-1635	423
1994	The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. 2020 , 25, 522-544	9
1993	Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. 2020 , 20, 3210-3215	14
1992	Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. 2020 , 396, 603-611	247
1991	Antibody responses in mild COVID-19 hospital staff. 2020 , 59, 102940	7
1990	Natural killer cell immunotypes related to COVID-19 disease severity. 2020 , 5,	183
1989	Deciphering SARS-CoV-2 Virologic and Immunologic Features. 2020 , 21,	12
1988	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. 2020 , 6, 18	66

1987	Antigenic variation of SARS-CoV-2 in response to immune pressure. 2020 , 30, 3548	12
1986	'Dark matter', second waves and epidemiological modelling. 2020 , 5,	7
1985	Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?. 2020 , 10, 605334	4
1984	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). 2020 , 11, 571481	28
1983	Biomodulina T (ImnunyVital) Restores T Cells and Helps Contain COVID-19. 2020 , 11, 606447	2
1982	Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. 2020 , 9,	34
1981	HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic. 2020 , 8,	11
1980	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. 2020 , 11, 6385	62
1979	Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. 2020 , 11, 596553	23
1978	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. 2020 , 8,	5
1977	Characterizing key attributes of COVID-19 transmission dynamics in China's original outbreak: Model-based estimations. 2020 , 2, 100042	17
1976	How our specialty can contribute and benefit from COVID-19 research. 2020 , 10, 1274-1275	
1975	British Journal of Biomedical Science in 2020. What have we learned?. 2020 , 77, 159-167	
1974	Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases. 2020 , 9, e1219	14
1973	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. 2020 , 6, 141	11
1972	Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. 2020 , 10, 21447	31
1971	Remembering seasonal coronaviruses. 2020 , 370, 1272-1273	19
1970	Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study. 2020 , 20, 934	10

1969	B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. 2020 , 11, 611004	35
1968	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. 2020 , 9,	11
1967	Epitope similarity cannot explain the pre-formed T cell immunity towards structural SARS-CoV-2 proteins. 2020 , 10, 18995	8
1966	Role of SARS-CoV-2 in Altering the RNA-Binding Protein and miRNA-Directed Post-Transcriptional Regulatory Networks in Humans. 2020 , 21,	16
1965	Relationship of 2D Affinity to T Cell Functional Outcomes. 2020 , 21,	2
1964	The COVID-19 pandemic through eyes of a NYC fertility center: a unique learning experience with often unexpected results. 2020 , 18, 105	3
1963	Association of contact to small children with a mild course of COVID-19. 2020 , 100, 314-315	7
1962	SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. 2020 , 6, 2238-2249	82
1961	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. 2020 , 370, 1339-1343	441
1960	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. 2020 , 8,	27
1959	Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains. 2020 , 11, 579480	23
1958	Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. 2020 , 11, 581076	2
1957	Epitope prediction and identification- adaptive T cell responses in humans. 2020 , 50, 101418	12
1956	Explaining among-country variation in COVID-19 case fatality rate. 2020 , 10, 18909	99
1955	SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. 2020 , 84, 104384	78
1954	Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. 2020 , 190, e185-e187	9
1953	What do differences in case fatality ratios between children and adults tell us about COVID-19?. 2020 , 56,	1
1952	The starting line for COVID-19 vaccine development. 2020 , 395, 1815-1816	16

1951	Shielding from covid-19 should be stratified by risk. 2020 , 369, m2063	41
1950	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. 2020 , 75, 2503-2541	58
1949	Elevated nucleoprotein-induced interferon- β release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay. 2020 , 81, 452-482	12
1948	Coping With COVID-19: Learning From Past Pandemics to Avoid Pitfalls and Panic. 2020 , 8, 155-165	10
1947	COVID-19 paraclinical diagnostic tools: Updates and future trends. 2020 , 68, 83-91	9
1946	COVID-19 breakthroughs: separating fact from fiction. 2020 , 287, 3612-3632	18
1945	Understanding heterogeneity to inform the public health response to COVID-19 in Canada. 2020 , 192, E684-E685	27
1944	SARS-CoV-2, "common cold" coronaviruses' cross-reactivity and "herd immunity": The razor of Ockham (1285-1347)?. 2020 , 12, 8647	3
1943	Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2?. 2020 , 319, E197-E202	31
1942	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. 2020 , 11, 1606	27
1941	Response to "COVID-19: room for treating T cell exhaustion?". 2020 , 24, 345	1
1940	Severe COVID-19 and aging: are monocytes the key?. 2020 , 42, 1051-1061	70
1939	The Laboratory Diagnosis of Coronavirus Disease 2019- Frequently Asked Questions. 2020 , 71, 2996-3001	27
1938	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. 2020 , 94,	63
1937	COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning. 2020 , 11, 1581	181
1936	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. 2020 , 53, 442-455.e4	151
1935	Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. 2020 , 161,	49
1934	[Basic principles of replication and immunology of SARS-CoV-2]. 2020 , 117, 609-614	5

1933	Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. 2020 , 20, 457-458	214
1932	COVID-19 in patients with lung cancer. 2020 , 31, 1386-1396	107
1931	Adaptive immunity to SARS-CoV-2. 2020 , 1, iqaa003	5
1930	An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. 2020 , 44, 215-227	14
1929	Challenges of COVID-19 in children in low- and middle-income countries. 2020 , 35, 70-74	61
1928	Ecological and epidemiological models are both useful for SARS-CoV-2. 2020 , 4, 1153-1154	9
1927	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). 2020 , 75, 2445-2476	81
1926	Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity. 2020 , 42, 1015-1019	11
1925	Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. 2020 , 144, 110049	29
1924	Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?. 2020 , 81, 816-846	172
1923	Mapping the T cell response to COVID-19. 2020 , 5, 112	7
1922	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. 2020 , 56, 106078	29
1921	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. 2020 , 257, 118056	89
1920	Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac. 2020 ,	10
1919	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. 2021 , 109, 49-53	12
1918	Aging in COVID-19: Vulnerability, immunity and intervention. 2021 , 65, 101205	193
1917	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. 2021 , 223, 389-398	136
1916	How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?. 2021 , 40, 72-107	19

1915	Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. 2021 , 22, 25-31		222
1914	Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. <i>Cell</i> , 2021 , 184, 460-475.e21	56.2	84
1913	T-cell dysregulation in COVID-19. 2021 , 538, 204-210		23
1912	Immunity to acute virus infections with advanced age. 2021 , 46, 45-58		3
1911	Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening. 2021 , 155, 343-353		21
1910	"Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom. 2021 , 75, e13674		27
1909	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53		13
1908	Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. 2021 , 72, 301-308		115
1907	MERS-CoV in Africa-an enigma with relevance to COVID-19. 2021 , 21, 303-305		2
1906	Severe SARS-CoV-2 disease in the context of a NF- κ B2 loss-of-function pathogenic variant. 2021 , 147, 532-544.e1		13
1905	DockCoV2: a drug database against SARS-CoV-2. 2021 , 49, D1152-D1159		17
1904	COVID-19: Discovery, diagnostics and drug development. 2021 , 74, 168-184		133
1903	Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection. 2021 , 58, 520-535		39
1902	A bioinformatic prediction of antigen presentation from SARS-CoV-2 spike protein revealed a theoretical correlation of HLA-DRB1*01 with COVID-19 fatality in Mexican population: An ecological approach. 2021 , 93, 2029-2038		16
1901	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. 2021 , 22, 74-85		235
1900	Development of multi-epitope peptide-based vaccines against SARS-CoV-2. 2021 , 44, 18-30		16
1899	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. 2021 , 17, 46-64		209
1898	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. 2021 , 236, 3366-3382		11

1897	The fragility of humoral immunity as a physiological safety marker for healthcare workers to return after COVID-19 convalescence. 2021 , 54, 141-143	
1896	Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. 2021 , 31, e2183	19
1895	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. 2021 , 27, 286.e7-286.e13	49
1894	Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach. 2021 , 764, 142810	34
1893	Whither immunity? The search for effective, durable immunity to coronavirus disease 2019 (COVID-19). 2021 , 42, 205-207	0
1892	T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic. 2021 , 21, 854-863	19
1891	Liver transplantation in a patient after COVID-19 - Rapid loss of antibodies and prolonged viral RNA shedding. 2021 , 21, 1629-1632	12
1890	T cell immunity to SARS-CoV-2 following natural infection and vaccination. 2021 , 538, 211-217	32
1889	Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. 2021 , 59,	36
1888	Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products. 2021 , 126, 206-207	3
1887	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. 2021 , 39, 197-201	34
1886	Deciphering the ins and outs of SARS-CoV-2-specific T cells. 2021 , 22, 8-9	1
1885	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. <i>Cell</i> , 2021 , 184, 169-183.e17	327
1884	Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. 2020 , 6, e10202	12
1883	The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. 2021 , 99, 93-106	11
1882	Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. 2021 , 268, 120584	11
1881	The Influence of Immune Immaturity on Outcome After Virus Infections. 2021 , 9, 641-650	1
1880	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. 2021 , 17, 1635-1649	9

1879	Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. 2020 ,	166
1878	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
1877	T Cells: Warriors of SARS-CoV-2 Infection. 2021 , 42, 18-30	65
1876	SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. 2021 , 223, 62-71	30
1875	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. 2021 , 371, 79-82	130
1874	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. 2021 , 538, 187-191	39
1873	Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile. 2021 , 206, 37-50	12
1872	COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals. 2021 , 29, 214-223	26
1871	Estimated effectiveness of school closure and voluntary event cancellation as COVID-19 countermeasures in Japan. 2021 , 27, 62-64	14
1870	Establishment of an African green monkey model for COVID-19 and protection against re-infection. 2021 , 22, 86-98	91
1869	Skin manifestations of COVID-19 in children: Part 3. 2021 , 46, 462-472	16
1868	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. 2021 , 21, 49-64	56
1867	A high-throughput multiplexed microfluidic device for COVID-19 serology assays. 2021 , 21, 93-104	20
1866	Characterization of pre-existing and induced SARS-CoV-2-specific CD8 T cells. 2021 , 27, 78-85	158
1865	Dysregulation of the immune response in coronavirus disease 2019. 2021 , 45, 702-707	22
1864	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. 2021 , 169, 168-189	35
1863	The Sheba Medical Center healthcare workers' children's school: can we open schools safely?. 2021 , 27, 474.e1-474.e3	1
1862	Enhanced SARS-CoV-2 neutralization by dimeric IgA. 2021 , 13,	178

1861	A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 and CD8 T Cells in COVID-19 Patients. 2021 , 206, 580-587	5
1860	Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. 2021 , 108, 187-196	40
1859	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. 2021 , 20, 139-153	6
1858	A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant. 2021 , 57, 504-507	15
1857	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
1856	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. 2021 , 27, 279-288	135
1855	COVID-19 outpatient management: Shorter time to recovery in Healthcare workers according to an electronic daily symptoms assessment. 2021 , 51, 71-76	0
1854	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. 2021 , 14, 305-316	83
1853	Viral targets for vaccines against COVID-19. 2021 , 21, 73-82	402
1852	T Cell Memory: Understanding COVID-19. 2021 , 54, 14-18	55
1851	COVID-19 in a case previously infected with MERS-CoV: No cross immunity. 2021 , 82, e28-e29	2
1850	PD-1-Expressing SARS-CoV-2-Specific CD8 T Cells Are Not Exhausted, but Functional in Patients with COVID-19. 2021 , 54, 44-52.e3	88
1849	COVID-19-Associated Suspected Myocarditis as the Etiology for Recurrent and Protracted Fever in an Otherwise Healthy Adult. 2021 , 361, 522-525	4
1848	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. 2021 , 31, 100689	112
1847	COVID-19 and Solid Organ Transplantation: A Review Article. 2021 , 105, 37-55	111
1846	Impact of COVID-19 in solid organ transplant recipients. 2021 , 21, 925-937	37
1845	Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. 2021 , 41, 720-730	23
1844	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. 2021 , 27, 122-129	42

1843	Biomarkers for the clinical development of antiviral therapies. 2021 , 100, 19-32	
1842	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 223, 56-61	42
1841	Background immunity: How important is it for SARS-CoV-2?. 2021 , 93, 1253-1254	
1840	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. 2021 , 40, 54-71	5
1839	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. 2021 , 223, 47-55	40
1838	T cell immunobiology and cytokine storm of COVID-19. 2021 , 93, e12989	25
1837	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. 2021 , 18, 936-944	62
1836	Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. 2021 , 41, 850-859	43
1835	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. 2021 , 87, 845-857	3
1834	Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge. 2021 , 64, 482-485	19
1833	Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. 2021 , 31, e2162	45
1832	T-cell responses and therapies against SARS-CoV-2 infection. 2021 , 162, 30-43	60
1831	Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. 2021 , 17, 620-637	1
1830	COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity. 2021 , 82, 282-327	18
1829	Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering. 2021 , 19, 518-529	9
1828	Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice. 2020 , 11, 602254	4
1827	CD8+ T cell epitope variations suggest a potential antigen presentation deficiency for spike protein of SARS-CoV-2.	1
1826	Characteristics of T-cell responses in COVID-19 patients with prolonged SARS-CoV-2 positivity - a cohort study. 2021 , 10, e1259	5

1825	Vaccines Safety and Effectiveness in the Midst of Covid-19 Mutations. 2021 , 13, 283-298		
1824	Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain. 2021 , 40, 1343-1349		1
1823	T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease. 2021 ,		13
1822	Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. 2021 , 17, e1009287		8
1821	Inhibitory Potential of Phytochemicals on Interleukin-6-Mediated T-Cell Reduction in COVID-19 Patients: A Computational Approach. 2021 , 15, 11779322211021430		2
1820	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021 , 184, 476-488.e11	56.2	270
1819	Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset. 2021 , 118,		15
1818	PathExNET: A tool for extracting pathway expression networks from gene expression statistics. 2021 , 19, 4336-4344		1
1817	Estimating the case fatality ratio for COVID-19 using a time-shifted distribution analysis. 2021 , 149, e197		1
1816	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. 2021 , 10, e1319		13
1815	Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. 2021 , 10,		44
1814	Comprehensive Meta-Analysis of COVID-19 Global Metabolomics Datasets. 2021 , 11,		36
1813	Role of the Immune Microenvironment in SARS-CoV-2 Infection. 2021 , 30, 9636897211010632		5
1812	Immune determinants of COVID-19 disease presentation and severity. 2021 , 27, 28-33		194
1811	Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity?. 2021 , 131,		8
1810	Immune response to SARS-CoV-2 in the nasal mucosa in children and adults. 2021 ,		6
1809	SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response. 2020 , 11, 618402		8
1808	A computational approach for designing novel SARS-CoV-2 Mpro inhibitors: combined QSAR, molecular docking, and molecular dynamics simulation techniques.		4

1807	Incorporating and addressing testing bias within estimates of epidemic dynamics for SARS-CoV-2. 2021 , 21, 11	3
1806	Prototype multi-biomarker test for point-of-care leprosy diagnostics. 2021 , 24, 102006	5
1805	Simulating and Epidemic Prediction of COVID-19 Transmission in Universities Considering Different Interventions. 2021 , 565-575	
1804	Case fatalities due to COVID-19: Why there is a difference between the East and West?. 2021 , 5, 56-63	
1803	HLA and immunodominance in viral infection: T-cell responses in protection and immunopathogenesis. 2021 , 42, 84	0
1802	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. 2021 , 18, 318-327	156
1801	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. 2021 , 12,	46
1800	BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. 2021 , 131,	62
1799	Production of the Receptor-binding Domain of the Viral Spike Proteins from 2003 and 2019 SARS CoVs and the Four Common Human Coronaviruses for Serologic Assays and Inhibitor Screening. 2021 , 11, e4026	
1798	Dysregulated Host Response in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Critical Illness. 2021 , 8, ofab019	5
1797	From the secrets of longevity... nutraceuticals [part V. Viral pathogenesis - theoretical approaches and natural practical solutions. 2021 , 1, 36	
1796	COVID-19 in children: Pathogenesis and current status. 2021 , 42, 8-15	14
1795	Illuminating the immunopathology of SARS-CoV-2. 2021 , 100, 33-41	6
1794	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. 2021 , 10, e1306	16
1793	Geographic Negative Correlation of Estimated Incidence between First and Second Waves of Coronavirus Disease 2019 (COVID-19) in Italy. 2021 , 9, 133	5
1792	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020 , 11, 618685	29
1791	Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. 2021 , 9,	15
1790	Evolution of antibody immunity to SARS-CoV-2. 2021 , 591, 639-644	652

1789	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.	
1788	Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. 2020 , 44, e20200198	1
1787	Akut- und Langzeitimmunität – Was serologische Tests wirklich über den Immunstatus preisgeben. 2021 , 10, 39-45	
1786	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. 2021 , 11, 2608	40
1785	SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. 2021 , 12, 541	32
1784	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. 2021 , 10, e1260	7
1783	Epilogue. 2021 , 1093-1100	
1782	Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19. 2021 , 19, 19	4
1781	SARS-CoV-2 and approaches for a testing and diagnostic strategy. 2021 , 9, 8157-8173	1
1780	At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. 2021 , 9, 261-264	8
1779	Adaptive immunity to human coronaviruses is widespread but low in magnitude.	2
1778	The Conundrum of Giglio Island: Unraveling the dynamics of an apparent resistance to COVID-19 - A descriptive study. 2021 , 19, 1467-1471	0
1777	Lessons in antiviral immunity. 2021 , 371, 464-465	10
1776	Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines. 2021 , 54, e10725	6
1775	Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. 2021 , 10, 664-676	32
1774	Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses. 2020 , 7, 594439	15
1773	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. 2021 , 11, 05005	40
1772	The evolutionary dynamics of endemic human coronaviruses. 2021 , 7, veab020	14

1771	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. 2021 , 27,	44
1770	Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals. 2021 , 10, e1281	9
1769	Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. 2021 , 27,	108
1768	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. 2021 , 17, e1009161	26
1767	Distinct antibody repertoires against endemic human coronaviruses in children and adults. 2021 , 6,	17
1766	Delay Differential Equations with Infectious Diseases. 2021 , 145-165	
1765	How vaccination and contact isolation might interact to suppress transmission of Covid-19: a DCM study.	0
1764	'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19.	1
1763	Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. 2020 , 11, 598402	14
1762	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. 2021 , 71, 342-358	0
1761	Endemic SARS-CoV-2 will maintain post-pandemic immunity. 2021 , 21, 131-132	29
1760	Epidemiological and clinical characteristics of 5,628 patients with coronavirus disease 2019 in South Korea: A nationwide multicenter study. 2021 , 9, 136	1
1759	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. 2021 , 7, e05951	6
1758	COVID-19, anorexia nervosa and obese patients with an eating disorder - some considerations for practitioners and researchers. 2021 , 9, 15	3
1757	COVID-19 and Pediatric Asthma: Clinical and Management Challenges. 2021 , 18,	11
1756	Hypothesis: Immunotherapy by Selective Convalescent Blood Engineering to Stifle Diseases like COVID-19. 2021 , 18, 3389-3394	
1755	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. 2021 ,	1
1754	Live attenuated coronavirus vaccines deficient in N7-Methyltransferase activity induce both humoral and cellular immune responses in mice. 2021 , 10, 1626-1637	8

1753	T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. 2021 , 10, e1341	7
1752	Persistent cellular immunity to SARS-CoV-2 infection. 2021 , 218,	59
1751	Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?. 2020 , 11, 571416	126
1750	Mapping and role of T cell response in SARS-CoV-2-infected mice. 2021 , 218,	41
1749	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. 2021 , 2, 100189	80
1748	Recent endemic coronavirus infection is associated with less-severe COVID-19. 2021 , 131,	141
1747	Delving Into the Origin of Destructive Inflammation in COVID-19: A Betrayal of Natural Host Defense Peptides?. 2020 , 11, 610024	2
1746	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered Lipid Nanoparticles. 2021 , 15, 9627-9637	32
1745	Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers. 2021 ,	1
1744	epitopepredict: a tool for integrated MHC binding prediction. 2021, 1-14	
1743	Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study. 2021 , 11, e043584	15
1742	Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. 2021 , 9,	9
1741	-----A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS-. 2021 , 6, 38	8
1740	Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature. 2021 , 11, 3461	12
1739	Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. 2021 , 36, 101051	38
1738	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. 2021 , 371,	1183
1737	COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. 2021 , 10,	6
1736	epitopepredict: A tool for integrated MHC binding prediction.	

1735	Immunological Characteristics of Non-Intensive Care Hospitalized COVID-19 Patients: A Preliminary Report. 2021 , 10,	1
1734	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. 2020 , 7, 629933	15
1733	SARS-CoV-2 antibody detection in skilled nursing facility residents. 2021 , 69, 1722-1728	4
1732	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. 2021 , 12, 1260	55
1731	Use of machine learning to identify a T cell response to SARS-CoV-2. 2021 , 2, 100192	7
1730	SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. 2021 , 9, 620730	22
1729	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. 2021 , 35, e21409	27
1728	Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients. 2021 , 12, 614599	18
1727	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. 2021 , 34, 108728	220
1726	Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. 2020 , 11, 634266	4
1725	COVID-19-from mucosal immunology to IBD patients. 2021 , 14, 566-573	7
1724	MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection. 2021 , 12,	9
1723	The analysis on the human protein domain targets and host-like interacting motifs for the MERS-CoV and SARS-CoV/CoV-2 infers the molecular mimicry of coronavirus. 2021 , 16, e0246901	2
1722	COVID-19 and immunity: quo vadis?. 2021 , 33, 507-513	4
1721	A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. 2021 , 7,	20
1720	Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19. 2021 , 12, 641900	45
1719	Unanticipated efficacy of SARS-CoV-2 vaccination in older adults. 2021 , 18, 7	9
1718	Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19.	2

1717	SARS-Cov-2 ORF3a: Mutability and function. 2021 , 170, 820-826	35
1716	Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity. 2021 , 95,	18
1715	The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. 2021 , 17, e1008559	77
1714	Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients. 2021 , 12, 603563	9
1713	Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity. 2021 , 118,	75
1712	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. 2021 , 12, 1162	136
1711	COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. 2021 , 54, 340-354.e6	87
1710	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. 2021 , 14, 38	40
1709	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. 2021 , 2, 100204	184
1708	Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition. 2021 , 12, 627186	3
1707	SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. 2021 ,	3
1706	Sampling SARS-CoV-2 Proteomes for Predicted CD8 T-Cell Epitopes as a Tool for Understanding Immunogenic Breadth and Rational Vaccine Design. 1,	0
1705	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. 2021 , 16, e0246731	3
1704	The impact of immuno-aging on SARS-CoV-2 vaccine development. 2021 , 43, 31-51	14
1703	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. 2021 , 12, 631139	43
1702	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. 2021 , 9,	62
1701	Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March-August, 2020. 2021 , 73, 1831-1839	2
1700	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 2021 , 592, 616-622	730


1699	Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19. 2021 , 29, 173-187	11
1698	A Longitudinal Study of the Epidemiology of Seasonal Coronaviruses in an African Birth Cohort. 2021 , 10, 607-614	1
1697	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. 2021 , 16, e0247665	3
1696	Peptides-based vaccine against SARS-CoV-2 antigenic fragmented synthetic epitopes recognized by T cell and -cell initiation of specific antibodies to fight the infection. 2021 , 4, 1-16	4
1695	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. 2021 ,	6
1694	Bergamo and Covid-19: How the Dark Can Turn to Light. 2021 , 8, 609440	6
1693	Homologies between SARS-CoV-2 and allergen proteins may direct T cell-mediated heterologous immune responses. 2021 , 11, 4792	7
1692	An Immunological Perspective: What Happened to Pregnant Women After Recovering From COVID-19?. 2021 , 12, 631044	3
1691	Identification of HLA-A*02:01-restricted candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 that may be natural targets of CD8 T cell recognition. 2020 ,	13
1690	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. 2021 , 131,	39
1689	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. 2021 , 12, 1018	46
1688	Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. 2021 ,	34
1687	Genome-wide analysis of Indian SARS-CoV-2 genomes to identify T-cell and B-cell epitopes from conserved regions based on immunogenicity and antigenicity. 2021 , 91, 107276	3
1686	Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study. 2021 , 36, 859-868	6
1685	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. 2021 , 14, 39	0
1684	Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. 2021 , 12, 897	36
1683	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. 2021 , 6, 48	46
1682	Development and deployment of COVID-19 vaccines for those most vulnerable. 2021 , 13,	32

1681	DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. 2021 , 11, 3125	7
1680	Humoral responses to SARS-CoV-2 by healthy and sick dogs during the COVID-19 pandemic in Spain. 2021 , 52, 22	11
1679	Current mutasome of SARS-CoV-2 in Turkey reveals mutations of interest. 2021 , 45, 104-113	5
1678	Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers. 2021 , 22,	18
1677	Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age. 2021 , 223, 1555-1563	2
1676	Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes. 2021 , 13,	7
1675	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021 , 184, 861-880	56.2 519
1674	The interplay between environmental exposures and COVID-19 risks in the health of children. 2021 , 20, 34	5
1673	Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19. 2021 , 22,	3
1672	Serum α -microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?. 2021 , 16, e0247758	2
1671	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. 2021 , 10, 63-85	16
1670	Simultaneous CD8 T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs. 2021 , 9,	7
1669	SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response.	1
1668	Cross sectional investigation of a COVID-19 outbreak at a London Army barracks: Neutralising antibodies and virus isolation. 2021 , 2, 100015	6
1667	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. 2021 , 11, 5934	13
1666	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. 2021 , 106, 1212-1217	12
1665	Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection. 2021 , 12, 636768	19
1664	The conundrum of current anti-SARS-CoV-2 vaccines. 2021 , 60, 46-51	3

1663	A randomised trial of in critically ill patients with COVID-19: ARMY-1. 2021 , 7,	5
1662	The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice.	4
1661	Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19. 2021 ,	4
1660	as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. 2021 , 9,	7
1659	miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery. 2021 , 7,	19
1658	The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. 2021 , 12, 637651	23
1657	The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. 2021 , 105, 2156-2164 ¹⁷	17
1656	The Relationship Between the Global Burden of Influenza From 2017 to 2019 and COVID-19: Descriptive Epidemiological Assessment. 2021 , 7, e24696	1
1655	Computational assessment of the spike protein antigenicity reveals diversity in B cell epitopes but stability in T cell epitopes across SARS-CoV-2 variants.	2
1654	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. 2021 , 9,	1
1653	Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. 2021 , 13, 197-209	2
1652	Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. 2021 , 10, 196	2
1651	Immune memory in convalescent patients with asymptomatic or mild COVID-19. 2021 , 7, 18	18
1650	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. 2021 , 10,	5
1649	Compounds of plants with activity against SARS-CoV-2 targets. 2021 , 14, 623-633	6
1648	Whole genome analysis of more than 10 000 SARS-CoV-2 virus unveils global genetic diversity and target region of NSP6. 2021 , 22, 1106-1121	6
1647	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021 , 7,	32
1646	Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?. 2021 , 23, e13602	4

1645	Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG lateral flow assay. 2021 , 16, e0247797	8
1644	Integrin Activation Enables Sensitive Detection of Functional CD4 and CD8 T Cells: Application to Characterize SARS-CoV-2 Immunity. 2021 , 12, 626308	1
1643	Negligible impact of SARS-CoV-2 variants on CD4 and CD8 T cell reactivity in COVID-19 exposed donors and vaccinees. 2021 ,	81
1642	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. 2021 , 22, 620-626	150
1641	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. 2021 , 34, 108863	40
1640	COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. 2021 , 12, 633680	30
1639	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 T cell responses. 2021 , 6,	58
1638	Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43. 2021 , 41, 952-960	11
1637	Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. 2021 ,	3
1636	Micro-scale technologies propel biology and medicine. 2021 , 15, 021302	0
1635	Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Stockholm, Sweden, 2009-2020. 2021 , 136, 104754	6
1634	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. 2021 , 2, 100208	46
1633	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. 2021 , 16, e0248007	15
1632	Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. 2021 , 224, 754-763	9
1631	Immunity to SARS-CoV-2: Lessons Learned. 2021 , 12, 654165	13
1630	Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. 2021 , 2, 281-295.e4	74
1629	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. 2021 , 6, 47	19
1628	The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. 2021 , 59,	41

1627	COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production. 2021 , 18, 20200982	6
1626	HIF-1, the Warburg Effect, and Macrophage/Microglia Polarization Potential Role in COVID-19 Pathogenesis. 2021 , 2021, 8841911	11
1625	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. 2021 , 8, 1-13	6
1624	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. 2021 , 10,	41
1623	Immune profiles of a COVID-19 adolescent with mild symptoms and anti-viral antibody deficiency. 2021 , 1, 117-123	1
1622	SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. 2021 , 80, 51-80	0
1621	Why Does SARS-CoV-2 Infection Induce Autoantibody Production?. 2021 , 10,	1
1620	Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic and SARS-CoV-2. 2021 , 7, 1596-1606	1
1619	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. 2021 , 13,	3
1618	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. 2021 ,	23
1617	Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly. 2021 , 10,	13
1616	Current progress and challenges in the design and development of a successful COVID-19 vaccine. 2021 , 1, 139-150	10
1615	Bovine Coronavirus Immune Milk Against COVID-19. 2021 , 12, 637152	5
1614	Correlates of Vaccine-Induced Protection against SARS-CoV-2. 2021 , 9,	26
1613	Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 224, 39-48	20
1612	Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. 2021 , 34, 108852	17
1611	Symptomatic Reinfection in Previously Recovered Coronavirus Disease 2019 (COVID-19) Geriatric Patient. 2021 , 13, e13961	
1610	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. 2021 ,	2

1609		0
1608	Lasting memories of SARS-CoV-2 infection. 2021 , 218,	2
1607	In-silico identification of subunit vaccine candidates against lung cancer-associated oncogenic viruses. 2021 , 130, 104215	3
1606	Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?. 2021 , 18, 12	12
1605	Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2. 2021 , 6,	5
1604	Recurrence of SARS-CoV-2 RNA among Positive Covid-19 Cases. 2021 , 11, 108-114	
1603	Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation. 2020 , 11, 623276	5
1602	Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands. 2021 , 67, 707-709	3
1601	Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. 2021 , 7,	28
1600	Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. 2021 , 147, 857-869.e7	10
1599	Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 2021 , 193, 692-696	10
1598	COVID-19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25	127
1597	Anti-SARS-CoV-2 Serology persistence over time in COVID-19 Convalescent Plasma Donors. 2021 ,	6
1596	Total predicted MHC-I epitope load is inversely associated with population mortality from SARS-CoV-2. 2021 , 2, 100221	10
1595	A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections. 2021 ,	5
1594	The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients. 2021 , 69, 5	1
1593	Relationship between lymphocyte subsets values and C-reactive protein in COVID-19 patients. 2021 , 99, 462-465	1
1592	Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma. 2021 , 11, 601709	1

1591	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. 2021 , 218,	97
1590	Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. 2021 , 12, 1724	38
1589	SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. 2021 , 131,	89
1588	A Case Series Describing the Recurrence of COVID-19 in Patients Who Recovered from Initial Illness in Bangladesh. 2021 , 6,	5
1587	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. 2021 , 11, 5538	22
1586	COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. 2021 ,	36
1585	COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?. 2021 , 9,	4
1584	Perspectives and Challenges in the Fight Against COVID-19: The Role of Genetic Variability. 2021 , 11, 598875	6
1583	Protein/AS01 vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. 2021 , 2, 100207	6
1582	Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. 2021 , 9, 2228-2235	3
1581	COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. 2021 , 254, 307-331	29
1580	The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. 2021 , 6, 113	15
1579	Lessons learned: new insights on the role of cytokines in COVID-19. 2021 , 22, 404-411	28
1578	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. 2021 , 7, 512-533	92
1577	Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015-20: a surveillance study. 2021 , 2, e105-e114	7
1576	The first 12 months of COVID-19: a timeline of immunological insights. 2021 , 21, 245-256	140
1575	Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in Health Care Workers.	6
1574	SARS-CoV-2 and immune-microbiome interactions: Lessons from respiratory viral infections. 2021 , 105, 540-550	10

1573	Circulating Adaptive Immune Cells Expressing the Gut Homing Marker $\alpha 4 \beta 7$ Integrin Are Decreased in COVID-19. 2021 , 12, 639329	3
1572	Immunity after SARS-CoV-2 infections. 2021 , 22, 539-540	8
1571	Predicting the severity of disease progression in COVID-19 at the individual and population level: A mathematical model. 2021 ,	
1570	Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits. 2021 , 19, 1245-1258	4
1569	Association of HLA-DRB1*09:01 with severe COVID-19. 2021 , 98, 37-42	12
1568	Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. 2021 ,	1
1567	Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19.	1
1566	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 Multi-Parameter Detection. 2021 , 12, 614676	4
1565	COVID-19 vaccines: Global challenges and prospects forum recommendations. 2021 , 105, 448-451	3
1564	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. 2021 , 131,	19
1563	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. 2021 , 21, 2749-2761	22
1562	The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. 2021 , 31, 720-722	65
1561	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. 2021 , 13,	14
1560	Landscapes of SARS-CoV-2-reactive CD8 T cells: heterogeneity of host immune responses against SARS-CoV-2. 2021 , 6, 146	1
1559	COVID-19: captures iron and generates reactive oxygen species to damage the human immune system. 2021 , 54, 213-224	11
1558	How to Understand Herd Immunity in the Context of COVID-19. 2021 , 34, 174-181	9
1557	SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. 2021 , 12, 627568	2
1556	Epigenome-wide association study of COVID-19 severity with respiratory failure. 2021 , 66, 103339	33

1555	Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects. 2021 , 000, 000-000	
1554	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVID-19 patients. 2021 ,	2
1553	The Neurobiology of Modern Viral Scourges: ZIKV and COVID-19. 2021 , 10738584211009149	1
1552	Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. 2021 ,	44
1551	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. 2021 , 12, 2055	37
1550	Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination.	15
1549	T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. 2021 , 13,	54
1548	Current updates on adaptive immune response by B cell and T cell stimulation and therapeutic strategies for novel coronavirus disease 2019 (COVID-19) treatment. 2021 , 7, e06894	3
1547	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. 2021 , 8, ofab217	16
1546	Upregulation of CCR4 in activated CD8 T cells indicates enhanced lung homing in patients with severe acute SARS-CoV-2 infection. 2021 , 51, 1436-1448	12
1545	COVID-19 immunity and vaccines: what a pharmacist needs to know. 2021 , 15, 51-67	
1544	COVID-19 serology in nephrology healthcare workers. 2021 , 133, 923-930	3
1543	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. 2021 , 137, 3165-3173	274
1542	Adherence to Public Health Measures Mitigates the Risk of COVID-19 Infection in Older Adults: A Community-Based Study. 2021 , 96, 912-920	1
1541	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. 2021 , 180, 106355	14
1540	Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. 2021 , 13,	6
1539	Strategies for Immunomonitoring after Vaccination and during Infection. 2021 , 9,	4
1538	Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. 2021 , 3, 100014	13

1537	The C-Terminal Domain of Nef Is Dispensable for the CD8 T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. 2021 , 9,		1
1536	Spectrum and Clinical Characteristics of Symptomatic and Asymptomatic Coronavirus Disease 2019 (COVID-19) With and Without Pneumonia. 2021 , 8, 645651		11
1535	Structural Consequences of Variation in SARS-CoV-2 B.1.1.7. 2021 , 3, 103-108		15
1534	Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19. 2021 , 89, 104712		4
1533	In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. 2021 , 171, 29-47		29
1532	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. <i>Cell</i> , 2021 , 184, 1858-1864.e10	56.2	155
1531	Assessment of humoral responses in COVID-19 using various quantitative antibody tests. 2021 , 58, 368-376		0
1530	A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques.		2
1529	Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. 2021 , 76, 1010-1019		16
1528	Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2. 2021 , 24, 102311		6
1527	A Perspective on COVID-19 Management. 2021 , 10,		3
1526	Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques. 2021 ,		3
1525	Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals. 2021 , 4, 486		7
1524	Could Antigen Presenting Cells Represent a Protective Element during SARS-CoV-2 Infection in Children?. 2021 , 10,		5
1523	Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients. 2021 , 73, 2073-2082		4
1522	Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. 2021 , 17, 421-430		8
1521	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. 2021 , 131,		65
1520	Protracted yet coordinated differentiation of long-lived SARS-CoV-2-specific CD8+ T cells during COVID-19 convalescence. 2021 ,		3

1519	COVID-19 and the human innate immune system. <i>Cell</i> , 2021 , 184, 1671-1692	56.2	175
1518	Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity. 2021 ,		3
1517	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. 2021 , 82, 58-66		25
1516	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. 2021 , 15, 5793-5818		13
1515	Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. 2021 , 35, e21577		6
1514	Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far?. 2021 , 31, e2236		4
1513	Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines. 2021 , 47, 673-684		1
1512	Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19. 2021 , 70, 1605-1608		8
1511	Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). 2021 , 105, 304-306		24
1510	Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. 2021 , 177, 112969		6
1509	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. 2021 , 11, 639108		2
1508	Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. 2021 , 26,		15
1507	Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. 2021 , 181, 450-460		143
1506	Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. 2021 , 136, 111272		42
1505	INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19. 2021 , 2, 29-35		6
1504	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. 2021 , 58, 1-15		28
1503	Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. 2021 , 54, 797-814.e6		94
1502	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021 , 184, 2384-2393.e13	56.2	459

1501	Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. 2021 , 224, 70-80	14
1500	Haemophilus influenzae and SARS-CoV-2: Is there a role for investigation?. 2021 , 39, 240-244	1
1499	Resourcing, annotating, and analysing synthetic peptides of SARS-CoV-2 for immunopeptidomics and other immunological studies. 2021 , 21, e2100036	2
1498	SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 T cell activation in COVID-19 patients. 2021 , 6,	65
1497	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. 2021 , 12, 2117	34
1496	Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay. 2021 , 105, 21-25	18
1495	Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. 2021 , 96, 989-1005	9
1494	Progress in research on the S protein as the target of COVID-19 vaccines. 2021 , 20, 769-772	2
1493	Microarray patches enable the development of skin-targeted vaccines against COVID-19. 2021 , 171, 164-186	22
1492	Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants.	5
1491	Genome-Wide B Cell, CD4, and CD8 T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines. 2021 , 206, 2566-2582	12
1490	Accelerated Progression of Disseminated Coccidioidomycosis Following SARS-CoV-2 Infection: A Case Report. 2021 , 186, 1254-1256	6
1489	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. 2021 , 42, 312-322	35
1488	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. 2021 , 93, 107364	25
1487	COVID-19 and Cardiovascular Disease: From Bench to Bedside. 2021 , 128, 1214-1236	57
1486	IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. 2021 , 22,	7
1485	Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection. 2021 , 376, 20200266	8
1484	Combination of a Sindbis-SARS-CoV-2 spike vaccine and 0X40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity. 2021 ,	3

1483	Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. 2021 , 11, 1982-1995	12
1482	Pre-existing T Cell Memory against Zika Virus. 2021 , 95,	2
1481	Identification of Novel Candidate CD8 T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses. 2021 , 13,	1
1480	Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection. 2021 , 23, 980-984	0
1479	Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2. 2021 , 12, 660019	6
1478	Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013-2017. 2021 , 9,	0
1477	Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects. 2021 , 413, 4137-4159	26
1476	Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination. 2021 , 206, 2503-2507	3
1475	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. 2021 ,	14
1474	Cytokines and Leukocytes Subpopulations Profile in SARS-CoV-2 Patients Depending on the CT Score Severity. 2021 , 13,	6
1473	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. 2021 , 12, 2938	110
1472	Does blood type affect the COVID-19 infection pattern?. 2021 , 16, e0251535	12
1471	IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. 2021 , 6,	7
1470	SARS-CoV-2 vaccines for cancer patients: a call to action. 2021 , 148, 316-327	26
1469	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. 2021 ,	19
1468	Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths. 2021 , 9,	6
1467	Adaptive immune responses to SARS-CoV-2. 2021 , 172, 1-8	3
1466	Regulatory KIR RA T cells accumulate with age and are highly activated during viral respiratory disease. 2021 , 20, e13372	2

1465	Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults. 2021 , 180, 3335-3342	12
1464	CD8 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. 2021 , 54, 1055-1065.e5	43
1463	Antigenic Evolution on a Global Scale Reveals the Potential Natural Selection of Severe Acute Respiratory Syndrome-Coronavirus 2 by Pre-existing Cross-Reactive T-Cell Immunity. 2021 , 12, 599562	4
1462	HERV-W envelope expression in blood leukocytes as a marker of disease severity of COVID-19. 2021 , 67, 103363	6
1461	A clinical staging proposal of the disease course over time in non-severe patients with coronavirus disease 2019. 2021 , 11, 10681	1
1460	How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology.	
1459	A novel application of delayed-type hypersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals. 2021 , 226, 108730	7
1458	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. 2021 , 44, 499-513	4
1457	A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein. 2021 , 9, 905-917	1
1456	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. 2021 , 20, 76	5
1455	Targets and strategies for vaccine development against SARS-CoV-2. 2021 , 137, 111254	32
1454	Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells. 2021 , 11, 9561	1
1453	IL-1A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS. 2021 , 6, 38	12
1452	Coronavirus Disease 19 and Future Ecological Crises: Hopes from Epigenomics and Unraveling Genome Regulation in Humans and Infectious Agents. 2021 , 25, 269-278	0
1451	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. 2021 , 106, 338-347	17
1450	Mining of linear B cell epitopes of SARS-CoV-2 ORF8 protein from COVID-19 patients. 2021 , 10, 1016-1023	2
1449	CD4 T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein. 2021 , 12, 629102	3
1448	Recurrence of COVID-19 after recovery ? A case series in health care workers, France. 2021 , 23, 104803	6

1447	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 2021 , 35, 109179	20
1446	The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant. 2021 , 36, 1761-1764	11
1445	Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family. 2021 ,	3
1444	Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older.	13
1443	Peripheral and lung resident memory T cell responses against SARS-CoV-2. 2021 , 12, 3010	29
1442	Dysregulation of Pulmonary Responses in Severe COVID-19. 2021 , 13,	8
1441	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. 2021 , 27, 1071-1078	66
1440	Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. 2021 , 372, 1336-1341	33
1439	False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. 2021 , 12, 666114	8
1438	SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. 2021 , 6,	185
1437	Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19. 2021 , 13,	1
1436	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. 2021 , 9,	4
1435	Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles. 2021 , 2021, 5531220	4
1434	H-Watch: An Open, Connected Platform for AI-Enhanced COVID19 Infection Symptoms Monitoring and Contact Tracing.. 2021 ,	2
1433	Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. 2021 , 9,	10
1432	Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity. 2021 , 13,	4
1431	Navigating in Deep Waters: How Tissue Damage and Inflammation Shape Effector and Memory CD8 T Cell Responses. 2021 , 5, 338-348	2
1430	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. 2021 , 172, 314-338	36

1429	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. 2021 , 2, 100290	68
1428	CD8 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. 2021 , 54, 1066-1082.e5	34
1427	Identification of T Cell Epitopes in the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 in Rhesus Macaques. 2021 , 206, 2527-2535	1
1426	Development of leading first-generation vaccines against SARS-CoV-2. 2021 , 23, 104841	
1425	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. 2021 , 1-16	1
1424	Highly Functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection.	0
1423	Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. 2021 , 35, 109164	10
1422	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. 2021 , 56, 1493-1508	7
1421	Identification and characterization of a SARS-CoV-2 specific CD8 T cell response with immunodominant features. 2021 , 12, 2593	25
1420	Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. 2021 , 41, 1146-1153	19
1419	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. 2021 , 21, 637-646	170
1418	Identification of risk and protective human leukocyte antigens in COVID-19 using genotyping and structural modeling.	
1417	Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection. 2021 , 7, 121-131	
1416	Comparison of Reverse-Transcription Polymerase Chain Reaction Cycle Threshold Values From Respiratory Specimens in Symptomatic and Asymptomatic Children With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021 , 73, 1790-1794	4
1415	Bioinformatic HLA Studies in the Context of SARS-CoV-2 Pandemic and Review on Association of HLA Alleles with Preexisting Medical Conditions. 2021 , 2021, 6693909	1
1414	Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus. 2021 , 6,	3
1413	Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. 2021 , 13, e14045	12
1412	Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. 2021 , 12, 666163	5

1411	AIDS and COVID: A tale of two pandemics and the role of statisticians. 2021 , 40, 2499-2510	7
1410	Immune Responses in Patients with COVID-19: An Overview. 2021 , 50, e222-e226	0
1409	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. 2021 , 12, 688436	6
1408	Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice. 2021 , 10,	4
1407	Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate.	8
1406	Management of COVID-19: current status and future prospects. 2021 , 23, 104832	6
1405	OMIP 075: A 22-color panel for the measurement of antigen-specific T-cell responses in human and nonhuman primates. 2021 , 99, 884-887	1
1404	Global characterization of B cell receptor repertoire in COVID-19 patients by single-cell V(D)J sequencing. 2021 , 22,	6
1403	Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. 2021 ,	1
1402	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. 2021 , 9,	12
1401	Cross-reactive antibody immunity against SARS-CoV-2 in children and adults. 2021 , 18, 1826-1828	12
1400	Immune response scenario and vaccine development for SARS-CoV-2 infection. 2021 , 94, 107439	5
1399	Understanding COVID-19: are children the key?. 2021 , 5, e001063	3
1398	Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform. 2021 , 2, 100312	13
1397	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. 2021 , 6, 213	29
1396	The dawn of mRNA vaccines: The COVID-19 case. 2021 , 333, 511-520	94
1395	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. 2021 , 6, 71	10
1394	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. 2021 , 82, 162-169	27

1393	Heterologous vaccine interventions: boosting immunity against future pandemics. 2021 , 27, 54	5
1392	A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. 2021 , 12, 674279	1
1391	COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay.	
1390	The impact of school reopening on the spread of COVID-19 in England. 2021 , 376, 20200261	23
1389	Dynamic causal modelling of immune heterogeneity. 2021 , 11, 11400	2
1388	Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes. 2021 , 12, 3006	5
1387	Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. 2021 , 12, 635942	8
1386	Symptomatic SARS-CoV-2 Reinfection in a Healthy Healthcare Worker in Italy Confirmed by Whole-Genome Sequencing. 2021 , 13,	3
1385	The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-II 2021 , 118,	112
1384	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. 2021 , 595, 572-577	213
1383	Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals. 2021 , 11, 13164	6
1382	A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. 2021 , 12, 684152	1
1381	Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. 2021 , 21, 544	7
1380	Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination. 2021 ,	1
1379	SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. 2021 , 68, 103410	19
1378	Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. 2021 , 232, 60-74	29
1377	Future considerations for the mRNA-lipid nanoparticle vaccine platform. 2021 , 48, 65-72	23
1376	Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review. 2021 , 20, 1-23	9

1375	COVID-19: individual and herd immunity. 2021 , 344, 7-18	0
1374	SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. 2021 , 11, 12312	11
1373	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. 2021 , 99, 577-588	
1372	Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. 2021 ,	8
1371	Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2.	1
1370	SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection. 2021 , 100, 115338	4
1369	Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. 2021 , 2, 682-688.e4	56
1368	SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study. 2021 , 27, 916.e1-916.e4	6
1367	A reasoned approach towards administering COVID-19 vaccines to pregnant women. 2021 , 41, 1018-1035	3
1366	Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. 2021 , 76, 2866-2881	15
1365	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. 2021 , 12, 658519	24
1364	Immunological imprinting of the antibody response in COVID-19 patients. 2021 , 12, 3781	51
1363	Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. 2021 , 6,	8
1362	Human CD4 T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. 2021 , 205, 363-378	7
1361	The Immunopathobiology of SARS-CoV-2 Infection. 2021 , 45,	1
1360	Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. 2021 , 38, 3550-3588	12
1359	Immuno-thrombosis in Acute Respiratory Dysfunction of COVID-19. 2021 , 12, 651545	3
1358	Cerebrovascular complications of novel coronavirus infection in young and middle-aged people. 2021 , 21-25	

1357	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. 2021 , 139, 104847	12
1356	Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters. 2021 , 148, 94-100	7
1355	Covid-19 Reinfection Dynamics-Is Immunity Short Lasting? Case Series of Healthcare Workers. 2021 , 11, 105-107	
1354	Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines. 2021 , 9, 40	3
1353	Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort. 2021 , 10,	
1352	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. 2021 , 9,	2
1351	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. 2021 , 12, 701752	8
1350	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. 2021 , 194, 999-1006	24
1349	Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. 2021 , 150, 1-9	11
1348	Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. 2021 , 131,	23
1347	A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants.	2
1346	Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019. 2021 , 224, 956-966	1
1345	COVID-19 (SARS-CoV-2) lymphocyte responses are associated with inflammatory biomarkers in total joint replacement surgery candidates pre-operatively. 2021 , 16, 415	
1344	Targeting Future Pandemics, a Case for Purine Synthesis and Basic Research. 2021 , 12, 694300	0
1343	Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. 2021 , 35, 109305	3
1342	Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19. 2021 , 10,	11
1341	COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. 2021 , 18, 705-715	9
1340	Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals. 2021 , 6,	3

1339	SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. 2021 , 12, 4043	53
1338	Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. 2021 , 175, 586-593	61
1337	Analysis of cell-mediated immunity in people with long COVID.	1
1336	Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study. 2021 , 18, 126	4
1335	High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. 2021 , 1, 4	6
1334	Phenotypes and Functions of SARS-CoV-2-Reactive T Cells. 2021 , 44, 401-407	5
1333	An overview of some potential immunotherapeutic options against COVID-19. 2021 , 95, 107516	6
1332	Vaccination reshapes the virus-specific T cell repertoire in unexposed adults. 2021 , 54, 1245-1256.e5	2
1331	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. 2021 , 9, 622-642	121
1330	Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?. 2021 , 6, 80	4
1329	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells. 2021 ,	4
1328	Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope.	4
1327	Maintenance of the human memory T cell repertoire by subset and tissue site. 2021 , 13, 100	5
1326	Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients. 2021 ,	9
1325	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. 2021 , 54, 1290-1303.e7	35
1324	IFN- γ cell response and IFN- γ release concordance after in vitro SARS-CoV-2 stimulation. 2021 , 51, e13636	2
1323	Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. 2021 , 13, 503-518	0
1322	Yeast display of MHC-II enables rapid identification of peptide ligands from protein antigens (RIPPA). 2021 , 18, 1847-1860	1

1321	An Overview About the Role of Adaptive Immunity in Keeping SARS-CoV-2 Reinfections at Bay. 2021 , 34, 588-596	1
1320	Antibody and viral RNA kinetics in SARS-CoV2 infected patients admitted to a Romanian University Hospital of Infectious Diseases. 2021 , 107, 205-211	0
1319	Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples. 2021 , 224, 1305-1315	5
1318	Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4 T cell help. 2021 , 35, 109320	17
1317	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. 2021 , 95, e0040421	14
1316	A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. 2021 , 36, 100902	19
1315	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. 2021 , 595, 426-431	247
1314	The Beauty of Simplicity: Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Responses in RNA-SARS-Cov-2 Vaccinated Individuals. 2021 , 9,	1
1313	SARS coronavirus vaccines protect against different coronaviruses.	1
1312	Single-nucleotide conservation state annotation of the SARS-CoV-2 genome. 2021 , 4, 698	
1311	Production of SARS-CoV-2 Specific IFN- γ /IL-10 Co-producing CD4 T Cells from Convalescent Donors to Treat COVID-19: A Hypothesis. 2021 , 000, 000-000	
1310	Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus. 2021 , 38, 101139	18
1309	The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. 2021 , 95, 107586	11
1308	T Cell Specificity: A Great Challenge in Chagas Disease. 2021 , 12, 674078	0
1307	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. 2021 , 558, 13-21	11
1306	Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. 2022 , 71, 226-229	15
1305	Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. 2021 , 118,	25
1304	Young infants exhibit robust functional antibody responses and restrained IFN- γ production to SARS-CoV-2. 2021 , 2, 100327	6

1303	Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19. 2021 , 11, 11462	2
1302	Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection. 2021 , 224, 1294-1304	19
1301	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. 2021 , 73, 2000-2008	17
1300	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. 2021 , 34, 1025-1037	0
1299	SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'. 2021 , 12, 4383	12
1298	Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'. 2021 , 12, 4515	5
1297	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. 2021 , 10,	9
1296	COVID-19.	
1295	Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. 2021 , 10,	13
1294	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. 2021 , 27, 1784-1789	15
1293	Development of rapid and cost-effective top-loading device for the detection of anti-SARS-CoV-2 IgG/IgM antibodies. 2021 , 11, 14926	1
1292	How to interpret and use COVID-19 serology and immunology tests. 2021 , 27, 981-986	23
1291	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. 2021 , 1, 4-13	1
1290	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. 2021 , 12, 701501	35
1289	Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. 2021 ,	11
1288	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. 2021 , 27, 1029-1034	19
1287	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. 2021 , 36, 109414	19
1286	Anti-SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination.	7

1285	SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. 2021 , 29, 1076-1092	59
1284	Individual , and Genotypes Are No Major Factors Which Determine COVID-19 Severity. 2021 , 12, 698193	5
1283	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. <i>Cell</i> , 2021 , 184, 3962-3980.e17	56.2 26
1282	CD8 T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. 2021 , 6,	34
1281	Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. 2021 , 11, 14917	12
1280	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. 2021 , 17, e1009761	24
1279	Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020. 2021 , 11, 05014	0
1278	Identification of COVID-19 subtypes based on immunogenomic profiling. 2021 , 96, 107615	3
1277	Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults. 2021 , 9,	1
1276	Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments. 2021 , 12, 716407	12
1275	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? - The Summarising Review. 2021 , 66, 1603975	0
1274	Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology. 2021 , 32, 1833-1842	5
1273	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. 2021 , 29, 1137-1150.e6	68
1272	Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2. 2021 , 34, 504-509	3
1271	Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. 2021 , 21, e810-e816	7
1270	COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. 2021 , 22, e13313	7
1269	Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. 2021 , 36, 109432	8
1268	Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?. 2021 , 1	13

1267	Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. 2021 , 12, 687449	9
1266	The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN- γ production in vitro. 2021 , 96, 107797	7
1265	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. 2021 , 36, 109415	131
1264	SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. 2021 , 12, 4678	26
1263	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. 2021 , 14,	11
1262	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. 2021 , 12, 669357	3
1261	AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG. 2021 , 16, 4739-4753	4
1260	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. 2021 , 7, 1368-1380	5
1259	Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. 2021 , 2, 100355	194
1258	SARS-CoV-2 diagnostics: Towards a more comprehensive approach to routine patient testing. 2021 , 494, 113044	1
1257	Distinctive features of severe SARS-CoV-2 pneumonia. 2021 , 131,	16
1256	The Spike of SARS-CoV-2: Uniqueness and Applications. 2021 , 12, 663912	2
1255	Competent immune responses to SARS-CoV-2 variants in older adults following mRNA vaccination.	0
1254	Impaired Priming of SARS-CoV-2-Specific Naive CD8 T Cells in Older Subjects. 2021 , 12, 693054	4
1253	Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and α X40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. 2021 , 12, 719077	3
1252	The trans-omics landscape of COVID-19. 2021 , 12, 4543	17
1251	Insights into the virologic and immunologic features of SARS-COV-2. 2021 , 9, 5007-5018	1
1250	Prolonged humoral and cellular immunity in COVID-19-recovered patients. 2021 , 28, 4010-4015	4

1249	Recent updates on the possible reasons for the low incidence and morbidity of COVID-19 cases in Africa. 2021 , 45, 133	3
1248	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. 2021 , 31, R918-R929	79
1247	High-precision and cost-efficient sequencing for real-time COVID-19 surveillance. 2021 , 11, 13669	5
1246	A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2. 2021 , 9,	0
1245	Innate and Adaptive Immune Assessment at Admission to Predict Clinical Outcome in COVID-19 Patients. 2021 , 9,	2
1244	Detection of IFN γ -Secreting CD4 and CD8 Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2. 2021 , 13,	6
1243	Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection. 2021 , 36, 211-211	4
1242	Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. 2021 , 31, 49-60	11
1241	The Many Faces of JAKs and STATs Within the COVID-19 Storm. 2021 , 12, 690477	3
1240	The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. 2021 , 288, 5042-5054	1
1239	Two novel nomograms based on inflammatory cytokines or lymphocyte subsets to differentially diagnose severe or critical and Non-Severe COVID-19. 2021 , 13, 17961-17977	1
1238	The Relationship between Pre-Pandemic Interferon Gamma Release Assay Test Results and COVID-19 Infection: Potential Prognostic Value of Indeterminate IFN- Release Assay Results. 2021 , 2021, 1989277	1
1237	Quantitative Insight into Immunopathology of SARS-CoV-2 Infection. 2021 , 41, 244-257	
1236	Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19.. 2021 , 2,	0
1235	Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist. 2021 , 64, 11554-11569	4
1234	Mechanistic understanding of innate and adaptive immune responses in SARS-CoV-2 infection. 2021 , 135, 268-275	7
1233	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. 2021 , 11,	44
1232	Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination. 2021 ,	6

1231	Developing Acid-Responsive Glyco-Nanoplatform Based Vaccines for Enhanced Cytotoxic T-lymphocyte Responses Against Cancer and SARS-CoV-2. 2021 , 31, 2105059	4
1230	Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. 2021 , 17, e1009668	5
1229	Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. 2021 , 148, 996-1006.e18	7
1228	Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air. 2021 , 22,	3
1227	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. 2021 , 96, 107763	14
1226	A correlate of protection for SARS-CoV-2 vaccines is urgently needed. 2021 , 27, 1147-1148	72
1225	A Single-Cell Atlas of Lymphocyte Adaptive Immune Repertoires and Transcriptomes Reveals Age-Related Differences in Convalescent COVID-19 Patients. 2021 , 12, 701085	9
1224	Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19. 2021 , 12, 707205	3
1223	Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. 2021 , 11, 14232	7
1222	Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection. 2021 ,	2
1221	Similarities and differences in the conformational stability and reversibility of ORF8, an accessory protein of SARS-CoV-2, and its L84S variant. 2021 , 563, 92-97	2
1220	The conundrum of two-dose interval of ChAdOx1 nCoV-19 corona virus vaccine: Way ahead. 2021 , 77, S250-S253	2
1219	Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. 2021 , 78, 5953-5976	6
1218	Functional responsiveness of memory T cells from COVID-19 patients. 2021 , 365, 104363	8
1217	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. 2021 , 9,	2
1216	What the HEC happens around the heart during COVID-19?. 2021 , 116, 43	
1215	Identification of HLA-A2 restricted CD8 T cell epitopes in SARS-CoV-2 structural proteins. 2021 , 110, 1171-1180	1
1214	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. 2021 , 21, 475-484	143

1213	Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. 2021 , 277, 119503	2
1212	SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. 2021 , 6, 256	13
1211	Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges. 2021 , 9,	0
1210	Adaptive Immunity and the Risk of Autoreactivity in COVID-19. 2021 , 22,	7
1209	Isolation of Antibodies Against the Spike Protein of SARS-CoV from Pig Serum for Competitive Immunoassay. 2021 , 1-10	2
1208	Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. 2021 , 70, 103495	15
1207	Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals. 2021 , 2,	2
1206	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. 2021 , 11, 142	41
1205	The COVID-19 vaccine development: A pandemic paradigm. 2021 , 301, 198454	6
1204	Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. 2021 , 6,	20
1203	Rational optimization of a human neutralizing antibody of SARS-CoV-2. 2021 , 135, 104550	3
1202	Egypt's COVID-19 Recent Happenings and Perspectives: A Mini-Review. 2021 , 9, 696082	8
1201	Putative Role of Vitamin D for COVID-19 Vaccination. 2021 , 22,	5
1200	Immunological considerations and vaccines against COVID-19. 2021 , 7, 54-62	0
1199	Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. 2021 , 12, 4740	31
1198	Longitudinal analysis of antibody decay in convalescent COVID-19 patients. 2021 , 11, 16796	9
1197	Immunity to SARS-CoV-2 induced by infection or vaccination. 2021 ,	24
1196	Two-Step In Vitro Model to Evaluate the Cellular Immune Response to SARS-CoV-2. 2021 , 10,	1

1195	Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities. 2021 , 12, 601080	2
1194	Activation or exhaustion of CD8 T cells in patients with COVID-19. 2021 , 18, 2325-2333	12
1193	CIDO ontology updates and secondary analysis of host responses to COVID-19 infection based on ImmPort reports and literature. 2021 , 12, 18	2
1192	Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection. 2021 , 131,	4
1191	T-CoV: a comprehensive portal of HLA-peptide interactions affected by SARS-CoV-2 mutations. 2021 ,	9
1190	Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C. 2021 , 131,	7
1189	mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. 2021 ,	23
1188	Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021 , 184, 4401-4413.e10	10
1187	Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. 2021 , 6,	9
1186	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. 2021 , 8, 100098	5
1185	Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2. 2021 , 8, 710010	4
1184	Defective Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses in an Immunocompromised Individual With Prolonged Viral Replication. 2021 , 8, ofab359	0
1183	Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19. 2021 , 109, 261-268	5
1182	Cross-reactive CD4 T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. 2021 , 374, eabh1823	53
1181	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. 2021 , 174, 1572-1585	80
1180	Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults. 2021 , 229, 108782	6
1179	Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8 T Cells during Convalescence. 2021 , 207, 1344-1356	7
1178	Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. 2021 , 13,	0

1177	Profiling Human Cytomegalovirus-Specific T Cell Responses Reveals Novel Immunogenic Open Reading Frames. 2021 , 95, e0094021	0
1176	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. 2021 , 92, 104869	18
1175	SARS-CoV-2 vaccines - the biggest medical research project of the 21st century. 2021 , 49, 52-57	4
1174	Immunogenicity and antigenicity based T-cell and B-cell epitopes identification from conserved regions of 10664 SARS-CoV-2 genomes. 2021 , 92, 104823	2
1173	Immunity and security using holism, ambient intelligence, triangulation, and stigmergy: Sensitivity analysis confronts fake news and COVID-19 using open set transduction. 2021 , 1-18	
1172	Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity. 2021 , 18,	
1171	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. 2021 , 12, 4888	13
1170	Candidate Psychotropics against SARS - CoV - 2: A Narrative Review. 2021 , 46,	11
1169	Is diabetes mellitus a wrongdoer to COVID-19 severity?. 2021 , 178, 108936	3
1168	A prospective study of the protective effect of SARS-CoV-2-specific antibodies and T cells in Moscow residents.	1
1167	Seasonal betacoronavirus antibodies expansion post BNT161b2 vaccination associates with reduced SARS-CoV-2 VoCs neutralization.	
1166	PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage. 2021 , 12, 728936	1
1165	COVID-19: Relationship and Impact on Breastfeeding-A Systematic Review. 2021 , 13,	0
1164	COVID-19 diagnostic tests: Importance of the clinical context. 2021 , 157, 185-190	0
1163	Rarely Recognized Antibody Diversification in Covid-19 Evolution to Counteract Advanced SARS-CoV-2 Evasion Strategies, and Implications for Prophylactic Treatment. 2021 , 12, 624675	3
1162	SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity. 2021 ,	6
1161	BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity. 2021 , 12, 692729	14
1160	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. 2021 , 12, 5061	42

1159	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. 2021 , 7,	11
1158	Evolutionary trajectory of SARS-CoV-2 and emerging variants. 2021 , 18, 166	30
1157	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. 2021 , 14, 3459-3476	50
1156	Molecular insight into the genomic variation of SARS-CoV-2 strains from current outbreak. 2021 , 93, 107533	1
1155	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. 2021 , 6,	2
1154	Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. 2021 ,	7
1153	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. 2021 , 36, 109518	25
1152	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. 2021 , 109, 199-202	10
1151	Immune response to SARS-CoV-2 in children: A review of the current knowledge. 2021 , 5, e12283	5
1150	Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. 2021 , 122, 102682	3
1149	Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19.. 2021 , 1, 277-293	0
1148	[COVID-19 diagnostic tests: importance of the clinical context]. 2021 , 157, 185-190	1
1147	Vaccine-Induced Cellular Immunity against Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines. 2021 , 9,	2
1146	Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN- γ ELISpot. 2021 , 11,	2
1145	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. 2021 , 97, 107679	5
1144	Virus-Induced CD8 T-Cell Immunity and Its Exploitation to Contain the SARS-CoV-2 Pandemic. 2021 , 9,	2
1143	Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques. 2021 , 12, e0150321	12
1142	Effect estimates of COVID-19 non-pharmaceutical interventions are non-robust and highly model-dependent. 2021 , 136, 96-132	16

1141	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. 2021 , 29, 951-962.e3	13
1140	Impact of COVID-19 on psychological wellbeing. 2021 , 21, 100252	2
1139	Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains. 2021 ,	2
1138	Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response.	1
1137	Pediatric SARS-CoV-2 seroprevalence during mitigation procedures in Southwestern Pennsylvania. 2021 , 1, 100026	0
1136	Dynamics of a stochastic delay differential model for COVID-19 infection with asymptomatic infected and interacting people: Case study in the UAE. 2021 , 28, 104658	18
1135	Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. 2021 , 10,	7
1134	Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. 2021 ,	
1133	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. 2021 , 13, eabj2641	8
1132	Comprehensive Immune Profiling of a Kidney Transplant Recipient With Peri-Operative SARS-CoV-2 Infection: A Case Report. 2021 , 12, 753558	1
1131	Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates. 2021 ,	2
1130	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. 2021 , 3, e627-e637	47
1129	Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement. 2021 , 137, 105-113	6
1128	SARS-CoV-2 spike-specific memory B cells express markers of durable immunity after non-severe COVID-19 but not after severe disease. 2021 ,	1
1127	Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report. 2021 , 12, 758154	1
1126	A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults. 2021 , 16, e0256980	1
1125	Quantifying T Cell Cross-Reactivity: Influenza and Coronaviruses. 2021 , 13,	0
1124	COVID-19 Vaccines: Current Conditions and Future Prospects. 2021 , 10,	5

1123	Early IFN- β signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. 2021 , 54, 2650-2669.e14	31
1122	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. 2021 , 6, eabl4509	40
1121	Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. 2021 , 12, 742914	9
1120	Association of HLA genotypes, ABO blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19. 2021 , 26, 107	3
1119	Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. 2021 , 27, 1990-2001	138
1118	SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function. 2021 , 51, 2651-2664	2
1117	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. 2021 , 12, 5407	5
1116	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. 2021 ,	5
1115	Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. 2021 ,	17
1114	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. 2021 , 112, 300-317	4
1113	Immunity Profiling of COVID-19 Infection, Dynamic Variations of Lymphocyte Subsets, a Comparative Analysis on Four Different Groups. 2021 , 9,	5
1112	What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. 2021 ,	2
1111	Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. 2021 , 148, 739-749	58
1110	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. 2021 , 27, 423-436	1
1109	Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. 2021 , 12, 730051	2
1108	Local SARS-CoV-2 peptide-specific Immune Responses in Convalescent and Uninfected Human Lung Tissue Models. 2021 ,	2
1107	Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. 2021 , 54, 103142	0
1106	Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. 2021 , 22, 1428-1439	22

1105	Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. 2021 , 297, 101065	2
1104	HIV and SARS-CoV-2 Co-Infection: What are the Risks?. 2021 , 14, 3991-4014	1
1103	CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients. 2021 , 6,	1
1102	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. 2021 ,	1
1101	Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. 2021 , 12, 729837	3
1100	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. 2021 , 17, e1009804	7
1099	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. 2021 , 374, eabj9853	60
1098	Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease. 2021 , 105, 115539	
1097	Immune Responses against SARS-CoV-2-Questions and Experiences. 2021 , 9,	2
1096	Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. 2021 , 12, 742941	15
1095	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T1 response with a diverse TCR repertoire. 2021 , 13, eabj7211	20
1094	The BNT162b2 mRNA vaccine induces polyfunctional T cell responses with features of longevity.	
1093	Interleukin-21 in Viral Infections. 2021 , 22,	0
1092	The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. 2021 , 27, 423-437	26
1091	Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection. 2021 , 230, 108814	5
1090	A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. 2021 , 7, eabh1547	13
1089	Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae. 2021 , 12, e0159921	4
1088	Profiling CD8 T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. 2021 , 36, 109708	9

1087	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. 2021,	11
1086	Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. 2021,	15
1085	Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. 2021, 7, 89	2
1084	The Possible Role of Microbial Proteases in Facilitating SARS-CoV-2 Brain Invasion. 2021, 10,	0
1083	Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. 2021, 41,	4
1082	Design of Peptide Vaccine for COVID19: CD8+ and CD4+ T cell epitopes from SARS-CoV-2 open-reading-frame protein variants.	0
1081	Potential Cross-Reactive Immunity to COVID-19 Infection in Individuals With Laboratory-Confirmed MERS-CoV Infection: A National Retrospective Cohort Study From Saudi Arabia. 2021, 12, 727989	2
1080	Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals. 2021, 12, 709759	8
1079	No antibody response in cutaneous manifestations associated with COVID-19: An observational study of 64 cases with microbiological and clinical characterization. 2021, 34, e15142	
1078	Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. 2021,	11
1077	Breathing more breadth into COVID-19 T'cell responses. 2021, 2, 999-1001	1
1076	Protective heterologous T'cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. 2021, 2, 1050-1071.e7	10
1075	Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. 2021, 17, e1009842	6
1074	Nanotechnology-empowered vaccine delivery for enhancing CD8 T cells-mediated cellular immunity. 2021, 176, 113889	6
1073	The Immune Response to SARS-CoV-2 and Variants of Concern. 2021, 13,	6
1072	Rapid induction of antigen-specific CD4 T'cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. 2021, 54, 2133-2142.e3	117
1071	Immune signatures underlying post-acute COVID-19 lung sequelae. 2021, 6, eabk1741	16
1070	Liver injury in COVID-19: A Direct hit or Collateral damage?. 2021,	0

1069	Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19. 2021,	2
1068	Society for Maternal-Fetal Medicine Special Statement: COVID-19 research in pregnancy: progress and potential. 2021, 225, B19-B31	2
1067	Identification of resident memory CD8 T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. 2021, 6, eabk0894	15
1066	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. 2021, 11, 18182	22
1065	Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. 2021, 142, 104943	4
1064	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. 2021, 33, 529-540	5
1063	Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19. 2021, 15, 14347-14359	17
1062	Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. 2021, 17, e1009436	4
1061	SARS-CoV-2-specific T cells in infection and vaccination. 2021, 18, 2307-2312	42
1060	Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?. 2021, 9, 725606	2
1059	SARS-CoV-2, COVID-19 and the Ageing Immune System. 2021, 1, 769-782	34
1058	Specific CD8 TCR Repertoire Recognizing Conserved Antigens of SARS-CoV-2 in Unexposed Population: A Prerequisite for Broad-Spectrum CD8 T Cell Immunity. 2021, 9,	3
1057	Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. 2021, 148, 1481-1492.e2	7
1056	MHC Variants Associated With Symptomatic Asymptomatic SARS-CoV-2 Infection in Highly Exposed Individuals. 2021, 12, 742881	4
1055	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. 2021, 11, 690621	18
1054	Neutralizing antibody-independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion protein.	1
1053	From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry. 2021, 10,	7
1052	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. 2021, 27, 2002-2011	52

1051	Performance of the T-SPOT.COVID test for detecting SARS-CoV-2-responsive T cells. 2021 , 113, 155-161	6
1050	Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. 2021 , 278, 121159	5
1049	Antibodies to Seasonal Coronaviruses Rarely Cross-React With SARS-CoV-2: Findings From an African Birth Cohort. 2021 , 40, e516-e519	1
1048	Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. 2021 , 111, 68-75	3
1047	Absence of SARS-CoV-2 antibodies in pre-pandemic plasma from children and adults in Vietnam. 2021 , 111, 127-129	3
1046	Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. 2021 , 99, 108020	2
1045	Immune response to COVID-19 in older adults. 2021 , 40, 1082-1089	2
1044	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. 2021 , 100, 915-927	2
1043	Immunomodulation and immunotherapeutics of COVID-19. 2021 , 231, 108842	2
1042	Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases.. 2022 , 12, 1126-1147	2
1041	Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries. 2021 , 99, 108050	3
1040	Immunodominance complexity: lessons yet to be learned from dominant T cell responses to SARS-COV-2. 2021 , 50, 183-191	1
1039	SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. 2021 , 304, 198508	6
1038	Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients. 2021 , 137, 104792	3
1037	Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic health care workers. 2021 , 39, 6019-6024	1
1036	COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy. 2021 , 157, 441-449	13
1035	A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults. 2021 , 232, 108857	1
1034	Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. 2021 , 95, 105075	4

1033	The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients. 2021 , 4, 1-7	4
1032	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. 2021 , 145, 392-403	22
1031	Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis. 2021 , 19, 2347-2355	0
1030	Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers. 2021 , 8, ofab015	0
1029	Production of ORF8 protein from SARS-CoV-2 using an inducible virus-mediated expression system in suspension-cultured tobacco BY-2 cells. 2021 , 40, 433-436	7
1028	Stochastic Delay Differential Model for Coronavirus Infection COVID-19. 2021 , 253-275	0
1027	Principles and Challenges in anti-COVID-19 Vaccine Development. 2021 , 182, 339-349	22
1026	Adaptive immunity to human coronaviruses is widespread but low in magnitude. 2021 , 10, e1264	7
1025	Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome. 2021 , 16, 43-57	5
1024	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 2021 ,	54
1023	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. 2021 , 1,	2
1022	SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. 2021 , 21, e2	5
1021	Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India. 2021 , 115, 820-831	15
1020	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. 2021 , 63, 103197	11
1019	What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. 2021 , 36, e54	16
1018	Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts. 2021 , 10, e1340	2
1017	T cell response to SARS-CoV-2 infection in humans: A systematic review. 2021 , 16, e0245532	43
1016	Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective. 2021 , 4, 179-186	1

1015	A Flash on Cell Therapy Strategies in Clinical Trials against SARS-CoV-2. 2021 , 02,	
1014	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. 2021 , 21, e4	16
1013	Single Cell Transcriptomic Re-analysis of Immune Cells in Bronchoalveolar Lavage Fluids Reveals the Correlation of B Cell Characteristics and Disease Severity of Patients with SARS-CoV-2 Infection. 2021 , 21, e10	5
1012	Clinical and Epidemiological Characteristics of Common Human Coronaviruses in Children: A Single Center Study, 2015-2019. 2021 , 28, 101	1
1011	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection. 2021 , 73, e2992-e2994	9
1010	Attenuated Cd8+ T Cell Activation and Infiltration of the Lungs in Severe COVID-19.	
1009	Immunological and cardio-vascular pathologies associated with SARS-CoV-2 infection in golden syrian hamster.	6
1008	Clinical characteristics of COVID-19 patients with complications: implications for management. 2021 , 12, 20406223211041924	
1007	Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy. 2021 , 18, 314-324	11
1006	Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization. 2021 , 10,	33
1005	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. 2021 , 10, 797-809	15
1004	The chemical biology of coronavirus host-cell interactions. 2021 , 2, 30-46	2
1003	Pre-Existing Cellular Immunity to SARS-CoV-2 Through an Immunodominant Epitope.	1
1002	TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target. 2020 , 11, 601685	15
1001	The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2. 2021 , 12, 4	22
1000	501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab. 2021 , 13, 1919285	32
999	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. 2021 , 10, 507-535	61
998	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. 2021 , 2,	23

997	Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. 2021 , 590, 635-641	219
996	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. 2021 , 131,	41
995	The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. 2021 , 22,	35
994	Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8 T cells. 2021 , 6,	77
993	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. 2020 , 6,	1
992	Severe SARS-CoV-2 patients develop a higher specific T-cell response. 2020 , 9, e1217	14
991	Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. 2020 , 68, 315-324	32
990	Asthma-associated risk for COVID-19 development. 2020 , 146, 1295-1301	50
989	Coronaviruses pandemics: Can neutralizing antibodies help?. 2020 , 255, 117836	14
988	Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions. 2020 , 13, 100476	13
987	SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. 2020 , 1, 100081	88
986	Six months of coronavirus: the mysteries scientists are still racing to solve. 2020 , 583, 178-179	30
985	Coronavirus vaccines leap through safety trials - but which will work is anybody's guess. 2020 , 583, 669-670	4
984	Nature's second pandemic progress report. 2020 , 586, 473-474	2
983	How COVID-19 is changing the cold and flu season. 2020 , 588, 388-390	52
982	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. 2021 , 590, 320-325	74
981	Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs. 2020 , 10, 22375	27
980	Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology. 2020 , 40,	15

979	A pocket guide on how to structure SARS-CoV-2 drugs and therapies. 2020 , 48, 2625-2641	5
978	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
977	SARS-CoV-2 reinfection and implications for vaccine development. 2020 , 16, 3061-3073	23
976	Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. 2021 , 17, 1897-1909	14
975	Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity. 2021 , 218,	17
974	Five reasons COVID-19 is less severe in younger age-groups. 2021 , 9, 113-117	3
973	T cell phenotypes in COVID-19 - a living review. 2021 , 2, iqaa007	4
972	The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. 2021 , 16, 36-47	3
971	The Impact of SARS-CoV-2 on the Human Immune System and Microbiome. 2021 , 3, 14-21	3
970	The scale and dynamics of COVID-19 epidemics across Europe. 2020 , 7, 201726	15
969	SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. 2020 , 101, 1156-1169	86
968	Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach. 2020 ,	18
967	Iterative community-driven development of a SARS-CoV-2 tissue simulator. 2021 ,	18
966	Total predicted MHC-I epitope load is inversely associated with population mortality from SARS-CoV-2.	4
965	Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans.	59
964	Flatten the Curve! Modeling SARS-CoV-2/COVID-19 Growth in Germany at the County Level.	8
963	Robust computational design and evaluation of peptide vaccines for cellular immunity with application to SARS-CoV-2. 2020 ,	3
962	Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T cell memory formation after mild COVID-19 infection.	6

961	Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures.	11
960	Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. 2020,	52
959	CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains and influenza virus.	6
958	SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T-cell receptors.	10
957	An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations. 2020,	21
956	Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19. 2020,	18
955	Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals.	17
954	An open resource for T cell phenotype changes in COVID-19 identifies IL-10-producing regulatory T cells as characteristic of severe cases.	4
953	In Silico design and characterization of multi-epitopes vaccine for SARS-CoV2 from its spike proteins.	4
952	Suppressive myeloid cells are a hallmark of severe COVID-19.	10
951	Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity.	26
950	Systems-level immunomonitoring from acute to recovery phase of severe COVID-19.	13
949	The impact of school reopening on the spread of COVID-19 in England.	14
948	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. 2020,	47
947	Estimation of Individual Probabilities of COVID-19 Infection, Hospitalization, and Death From A County-level Contact of Unknown infection Status.	2
946	SARS-CoV-2-specific T cells exhibit unique features reflecting robust helper function, lack of terminal differentiation, and high proliferative potential. 2020,	14
945	A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis.	25
944	Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach.	1

943	Performance and health economic evaluation of the Mount Sinai COVID-19 serological assay identifies modification of thresholding as necessary to maximise specificity of the assay.	2
942	Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4 T cells. 2020,	26
941	A longitudinal study of immune cells in severe COVID-19 patients.	2
940	Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19.	10
939	SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients. 2020,	11
938	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.	2
937	Distinct antibody repertoires against endemic human coronaviruses in children and adults.	2
936	Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion.	54
935	Generation of SARS-CoV-2 S1 spike glycoprotein putative antigenic epitopes in vitro by intracellular aminopeptidases.	4
934	The impact of asymptomatic COVID-19 infections on future pandemic waves.	5
933	Modelling lockdown-induced 2ndCOVID waves in France.	7
932	SARS-CoV-2 serological testing using electrochemiluminescence reveals a rapid onset of seroconversion in severe COVID-19 patients.	2
931	Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.	85
930	A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection.	2
929	Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children.	14
928	SARS-CoV-2 reactive T cells in uninfected individuals are likely expanded by beta-coronaviruses.	7
927	Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine. 2020,	8
926	Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals.	3

925	Daily viral kinetics and innate and adaptive immune responses assessment in COVID-19: a case series.	6
924	SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques. 2020,	5
923	A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate.	11
922	High levels of SARS-CoV-2 specific T-cells with restricted functionality in patients with severe course of COVID-19.	1
921	Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 T cells. 2020,	6
920	Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis. 2020,	9
919	Neutralizing Antibody Responses in COVID-19 Convalescent Sera.	5
918	Single-nucleotide conservation state annotation of the SARS-CoV-2 genome. 2020,	1
917	The impact of host resistance on cumulative mortality and the threshold of herd immunity for SARS-CoV-2.	17
916	Antigenic variation of SARS-CoV-2 in response to immune pressure.	1
915	A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection.	5
914	An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19. 2020,	7
913	S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit.	3
912	Covid-19 serology in nephrology health care workers.	2
911	Herd immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics.	50
910	Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. 2020,	8
909	COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2.	7
908	Adopting STING agonist cyclic dinucleotides as a potential adjuvant for SARS-CoV-2 vaccine.	2

907	CoVaccine HT1b Adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation. 2020,	2
906	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.	13
905	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV. 2020,	14
904	Identification and characterization of CD4+ T cell epitopes after Shingrix vaccination.	1
903	A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses.	17
902	Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection.	3
901	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. 2020,	37
900	Alveolitis in severe SARS-CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar macrophages and T cells. 2020,	14
899	Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. 2020,	32
898	Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients.	7
897	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 2020,	38
896	Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. 2020,	2
895	Ex vivo detection of SARS-CoV-2-specific CD8+ T cells: rapid induction, prolonged contraction, and formation of functional memory.	6
894	Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine.	6
893	The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing.	2
892	Sampling SARS-CoV-2 proteomes for predicted CD8 T-cell epitopes as a tool for understanding immunogenic breadth and rational vaccine design.	0
891	High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.	5
890	Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge.	3

889	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 2020,	3
888	High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl.	15
887	The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.	14
886	SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time.	8
885	Induction of SARS-CoV-2 protein S-specific CD8+ T cells in the lungs of gp96-Ig-S vaccinated mice.	1
884	A longitudinal study of SARS-CoV-2 infected patients shows high correlation between neutralizing antibodies and COVID-19 severity.	3
883	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.	2
882	Dark matter second waves and epidemiological modelling.	3
881	Longitudinal single-cell immune profiling revealed distinct innate immune response in asymptomatic COVID-19 patients.	5
880	A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice.	18
879	Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2. 2020,	5
878	Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression. 2020,	7
877	Evolution of immunity to SARS-CoV-2.	6
876	Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152.	13
875	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. 2020,	15
874	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. 2020,	13
873	SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. 2020,	7
872	Inferring MHC interacting SARS-CoV-2 epitopes recognized by TCRs towards designing T cell-based vaccines.	1

871	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021,	8
870	Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. 2020,	3
869	Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.	3
868	Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland.	7
867	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. 2020,	40
866	Genome-Wide Asymptomatic B-Cell, CD4 and CD8 T-Cell Epitopes, that are Highly Conserved Between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines. 2020,	1
865	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.	7
864	SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-of-frame ORFs. 2020,	9
863	Updating Herd Immunity Models for the U.S. in 2020: Implications for the COVID-19 Response.	1
862	SARS-CoV-2-specific peripheral T follicular helper cells correlate with neutralizing antibodies and increase during convalescence. 2020,	4
861	CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation. 2020,	10
860	Prevalence and Longevity of SARS-CoV-2 Antibodies in Healthcare Workers: A Single Center Study.	0
859	Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1).	6
858	Healthcare workers with mild / asymptomatic SARS-CoV-2 infection show T cell responses and neutralising antibodies after the first wave.	5
857	Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis. 2020,	11
856	COVID-19 neutralizing antibodies predict disease severity and survival. 2020,	10
855	Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids.	1
854	Early induction of SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.	4

853	SARS-CoV-2 genome-wide mapping of CD8 T cell recognition reveals strong immunodominance and substantial CD8 T cell activation in COVID-19 patients.	1
852	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers.	7
851	Estimating the Case Fatality Ratio for COVID-19 using a Time-Shifted Distribution Analysis.	2
850	Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases.	1
849	Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered COVID-19 patients.	1
848	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells. 2020,	1
847	Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection.	24
846	SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers.	44
845	High attack rates of SARS-CoV-2 infection through household-transmission: a prospective study.	6
844	Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants.	3
843	Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals.	2
842	Evolution of Antibody Immunity to SARS-CoV-2. 2021,	43
841	Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2.	4
840	Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants.	32
839	Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection.	2
838	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19.	8
837	Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of Trento.	2
836	SARS-CoV-2 serological tests can generate false positive results for samples from patients with chronic inflammatory diseases.	2

835	Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation.	1
834	HIV status alters disease severity and immune cell responses in Δvariant SARS-CoV-2 infection wave.	15
833	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry. 2020,	6
832	T cell and antibody functional correlates of severe COVID-19. 2020,	6
831	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates.	12
830	Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity.	2
829	A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly Immunogenic and Prevents Lung Infection in an Adeno Associated Virus Human Angiotensin-Converting Enzyme 2 (AAV hACE2) Mouse Model.	5
828	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19.	2
827	Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses.	2
826	Persistent Cellular Immunity to SARS-CoV-2 Infection. 2020,	9
825	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. 2020,	11
824	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice.	5
823	Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. 2020, 202, 193-209	46
822	Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. 2021, 22, 372-378	52
821	Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. 2020, 5,	554
820	MAIT cell activation and dynamics associated with COVID-19 disease severity. 2020, 5,	74
819	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. 2020, 5,	98
818	Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs. 2020, 2020, 8827670	3

817	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. 2021 , 2, 9-12	11
816	Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão. 2020 , 54, 131	22
815	High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. 2020 , 5,	54
814	SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. 2020 , 130, 6477-6489	110
813	Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. 2020 , 130, 6588-6599	50
812	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. 2020 , 130, 6656-6667	55
811	Are T cells helpful for COVID-19: the relationship between response and risk. 2020 , 130, 6222-6224	7
810	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. 2020 , 130, 6366-6378	53
809	Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. 2020 , 130, 6631-6638	41
808	Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. 2020 , 130, 6204-6213	34
807	Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?. 2021 , 131,	7
806	Pre-COVID-19 lung function and other risk factors for severe COVID-19 in first responders. 2021 , 7,	5
805	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. 2020 , 18, 494	8
804	Stochastic SIRC epidemic model with time-delay for COVID-19. 2020 , 2020, 502	32
803	Convalescent Memory T Cell Immunity in Individuals with Mild or Asymptomatic SARS-CoV-2 Infection May Result from an Evolutionarily Adapted Immune Response to Coronavirus and the 'Common Cold'. 2020 , 26, e929789	2
802	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. 2020 , 9, 285	17
801	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. 2020 , 9, 285	13
800	Effective immunity and second waves: a dynamic causal modelling study. 2020 , 5, 204	3

799	SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study. 2020 , 15, e0240006	26
798	Estimating individual risks of COVID-19-associated hospitalization and death using publicly available data. 2020 , 15, e0243026	8
797	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. 2020 , 16, e1009163	12
796	SARS-CoV-2 serosurvey in health care workers of the Veneto Region. 2020 , 58, 2107-2111	52
795	Transmission of severe acute respiratory syndrome coronavirus 2 through asymptomatic carriers and aerosols: A major public health challenge. 2020 , 53, e20200669	4
794	Reversing immunosenescence for prevention of COVID-19. 2020 , 12, 11161-11162	7
793	Using the common cold virus as a naturally occurring vaccine to prevent COVID-19: Lessons from Edward Jenner. 2020 , 12, 18797-18803	4
792	A large-scale database of T-cell receptor beta (TCR β) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. 2020 ,	30
791	Driving Force of Covid-19 Among People Living With HIV/AIDS in Wuhan, China. 2020 ,	1
790	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. 2020 ,	7
789	Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. 2020 ,	8
788	Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 T Cells. 2020 , 3641939	25
787	Single-Dose Intranasal Vaccination Elicits Systemic and Mucosal Immunity Against SARS-CoV-2.	2
786	Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. 2020 , 15, 2883-2894	6
785	Vaccines against Coronavirus Disease: Target Proteins, Immune Responses, and Status of Ongoing Clinical Trials. 2020 , 14, 2253-2263	2
784	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. 2021 , 4,	25
783	Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19. 2020 , 20, 146-158	5
782	IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. 2020 , 35, e269	31

781	COVID-19 and the immune system. 2020 , 69, 379-388	138
780	Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures. 2020 , 11, 605170	38
779	Systems Thinking About SARS-CoV-2. 2020 , 8, 585229	6
778	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). 2021 , 58, 145-157	32
777	COVID-19 Vaccines: A Primer for Clinicians. 2020 , 49, e532-e536	5
776	Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment. 2020 , 6, 183-203	3
775	Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. 2020 , 4, 444-453	3
774	Coronavirus Receptors as Immune Modulators. 2021 , 206, 923-929	6
773	Why is There Low Morbidity and Mortality of COVID-19 in Africa?. 2020 , 103, 564-569	78
772	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. 2020 , 9,	14
771	Immunology of SARS-CoV-2 infections and vaccines. 2021 , 151, 49-97	3
770	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. 2021 , 224, 1849-1860	6
769	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. 2021 , 1313, 99-134	1
768	SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. 2021 , 14, 894-947	
767	Severity of COVID-19 in bacillus Calmette-Guérin vaccinated population. 2021 , 10, 276-281	2
766	Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. 2021 , 13,	5
765	When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. 2021 , 12, 692598	2
764	Caracterización y fisiopatología del Sars-Cov-2, Revisión de la literatura actual. 2021 , 34,	

763	SARS-CoV-2-Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals. 2021 , 207, 2581-2588	1
762	Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. 2021 , 12, 727850	12
761	Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response. 2021 ,	
760	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. 2021 , 13, 1805-1826	2
759	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. 2021 , 1-30	1
758	HIV status alters disease severity and immune cell responses in beta variant SARS-CoV-2 infection wave. 2021 , 10,	8
757	Long Term Immune Response Produced by the SputnikV Vaccine. 2021 , 22,	2
756	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. 2021 , 374, abm0829	133
755	Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. 2021 ,	4
754	T cell immunity to SARS-CoV-2. 2021 , 101505	11
753	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. 2021 , 39, 1442-1444	25
752	Importance of untested infectious individuals for interventions to suppress COVID-19. 2021 , 11, 20728	2
751	Relative Burdens of the COVID-19, Malaria, Tuberculosis, and HIV/AIDS Epidemics in Sub-Saharan Africa. 2021 ,	3
750	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. 2021 ,	69
749	Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. 2021 ,	14
748	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. 2021 , 101508	3
747	Cutting Edge: Lung-Resident T Cells Elicited by SARS-CoV-2 Do Not Mediate Protection against Secondary Infection. 2021 , 207, 2399-2404	2
746	Clinical and immunological characteristics in COVID-19 convalescent patients. 2021 , 40, 2669-2676	

745	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. 2021 , 10, 627-649	1
744	Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. 2021 , 43, 2321-2331	13
743	Comparing Humoral and Cellular Adaptive Immunity during Convalescent Phase of COVID-19 in Hemodialysis Patients and Kidney Transplant Recipients. 2021 , 10,	1
742	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. 2021 , 9, 1450-1466	31
741	COVID-19 outbreak among French firefighters, Marseille, France, 2020. 2021 , 26,	0
740	Impaired function and delayed regeneration of dendritic cells in COVID-19. 2021 , 17, e1009742	7
739	Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England. 2021 , 19, 275	10
738	Intragenomic rearrangements of SARS-CoV-2 and other β coronaviruses.	
737	Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge.. 2022 , 7, 36	3
736	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.	0
735	A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.. 2022 ,	8
734	COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines.. 2022 , 71, 377	1
733	Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period.. 2022 ,	0
732	Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2.. 2022 , 1-37	1
731	Driving force of COVID-19 among people living with HIV in Wuhan, China.. 2022 , 1-8	0
730	Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection.. 2021 , 12, 803031	3
729	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine.. 2022 , 10,	1
728	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2.. 2022 , 10,	

727	Hyperinflammatory State and Low T1 Adaptive Immune Response in Severe and Critical Acute COVID-19 Patients.. 2022 , 9, 828678	1
726	Dysfunctional State of T Cells or Exhaustion During Chronic Viral Infections and COVID-19: A Review.. 2022 ,	1
725	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues.. 2022 , 7, eabo0535	1
724	Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile.. 2022 ,	3
723	Characterization of memory T cell subsets and common Echain cytokines in convalescent COVID-19 individuals.. 2022 ,	2
722	Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients.. 2022 , 3, 100600	0
721	An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2.. 2022 , 10, e13136	1
720	T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.. 2022 , 78, 103967	3
719	Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women.. 2022 ,	1
718	Peptide candidates for the development of therapeutics and vaccines against Ecoronavirus infection.. 2022 , 13, 9435-9454	
717	Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.. 2022 , 22, 447	0
716	Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cT cells.. 2022 ,	0
715	Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.. 2022 ,	3
714	CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.. 2022 , 17, e0266691	
713	Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.. 2022 , 10,	
712	Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.. 2022 , 108991	2
711	Re-infection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to re-infection.. 2022 ,	3
710	In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.. 2022 ,	1

709	CD8 T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives.. 2022 , 13, 864298	1
708	Potency, toxicity and protection evaluation of PastroCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.. 2022 ,	1
707	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. 2022 ,	10
706	SARS-CoV-2 specific T-cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.. 2022 ,	0
705	Two sides of the same coin: Protective versus pathogenic CD4 resident memory T cells.. 2022 , 7, eabf9393	0
704	Systematic profiling of antigen bias in humoral response against SARS-CoV-2.. 2022 , 198711	
703	Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.. 2022 , 1	0
702	Maximizing COVID-19 Vaccine Acceptance in Developing Countries.	
701	Messenger Ribonucleic Acid Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 - A Review.. 2021 ,	1
700	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2.. 2022 ,	1
699	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells.. 2022 ,	7
698	The effect of age on the magnitude and longevity of Th1-directed CD4 T cell responses to SARS-CoV-2.. 2022 ,	0
697	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.. 2022 , 166, 229-239	0
696	Indiscriminate SARS-CoV-2 multivariant detection using magnetic nanoparticle-based electrochemical immunosensing.. 2022 , 243, 123356	5
695	Multifunctional role of exosomes in viral diseases: From transmission to diagnosis and therapy.. 2022 , 110325	1
694	Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models.. 2022 ,	0
693	Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients.. 2022 ,	0
692	Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection.. 2022 , 243, 123393	2

691	Immune Response to SARS-CoV-2 Vaccine in 2 Men. 2021 , 1-10	0
690	The immunologic response to severe acute respiratory syndrome coronavirus 2. 2021 , 42, 495-505	1
689	Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection.. 2021 , 9,	3
688	Kalkon T̄evli Bileklerin Covid-19 Tedavisine Ȳbelik SARS-CoV-2 Main Protease Enzimine Karđ Bađanma Mekanizmasđđ Molekđler Kenetlenme Ȳbtemi ile Aydđlatđmasđ	0
687	COVID-19 and gut immunomodulation.. 2021 , 27, 7925-7942	2
686	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.. 2021 , 11, e054208	2
685	mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship.. 2021 , 9,	2
684	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease.. 2021 , 16, e0261656	1
683	COVID-19 vaccine and immune response.	
682	ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2.. 2022 , 13, 30-45	1
681	Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination. 2021 ,	3
680	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals.. 2021 , 17, e1010203	3
679	Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.. 2021 , 44, 57	0
678	Modeling Early Phases of COVID-19 Pandemic in Northern Italy and Its Implication for Outbreak Diffusion.. 2021 , 9, 724362	0
677	Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population.. 2021 , 9,	2
676	HLA-A02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.. 2021 , 37, 110167	1
675	Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.. 2021 , 9,	1
674	Expansion of CD56CD16 NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients.. 2021 , 14,	2

673	TRKVEDE COVID-19 İE ENFEKTE OLAN SOLD ORGAN NAKİL HASTALARIN ACI SERVİS VE HASTANE BAURULARININ İCELENMESİ	0
672	Role of the cellular immunity in the formation of the immune response in coronavirus infections. 2021 , 23, 1229-1238	1
671	Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology.. 2021 , 11,	2
670	Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.. 2021 , 12, 802858	5
669	Analysis of TCR Repertoire by High-Throughput Sequencing Indicates the Feature of T Cell Immune Response after SARS-CoV-2 Infection.. 2021 , 11,	2
668	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. 2021 ,	5
667	A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.. 2021 , 17, e1010092	2
666	An update on host immunity correlates and prospects of re-infection in COVID-19.. 2021 , 1-26	0
665	Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation.. 2021 ,	2
664	Why Does the Severity of COVID-19 Differ With Age?: Understanding the Mechanisms Underlying the Age Gradient in Outcome Following SARS-CoV-2 Infection.. 2021 , 41,	3
663	Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.. 2021 , 12, 751869	2
662	CHARM: COVID-19 Health Action Response for Marines İassociation of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.	
661	T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.. 2021 , 8, 793102	4
660	Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination. 2021 , 100468	5
659	Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV. 2021 ,	6
658	TREM-2 is a sensor and activator of T cell response in SARS-CoV-2 infection. 2021 , 7, eabi6802	4
657	Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection.. 2021 , 17, e1009735	0
656	Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8 T cell responses following COVID-19.. 2022 , 23, 23-32	9

655	Recent and advanced nano-technological strategies for COVID-19 vaccine development. 2022,	
654	Unaltered T cell responses to common antigens in individuals with Parkinson's disease.	
653	Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.. 2022, 10, 867042	1
652	SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study.. 2022,	3
651	Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response.. 2022, 12, e802	1
650	Observations and perspectives on adaptive immunity to SARS-CoV-2.. 2022,	0
649	Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.. 2022, 1-11	1
648	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray.. 2022, 13, 817345	0
647	Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination.. 2022, 14,	1
646	Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort.. 2022,	
645	Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.. 2022, 1	
644	Long-Term, CD4 Memory T Cell Response to SARS-CoV-2.. 2022, 13, 800070	2
643	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell mediated immunity.. 2022,	0
642	Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.. 2022,	4
641	High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity.. 2022, 13, 867716	1
640	Transcriptomics of Acute DENV-Specific CD8+ T Cells Does Not Support Qualitative Differences as Drivers of Disease Severity.. 2022, 10,	0
639	Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self.. 2022, 101161CIRCRESAHA121320090	
638	The need for linked genomic surveillance of SARS-CoV-2.. 2022, 48, 131-139	1

637 An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells.. **2022**, 17, e0266412 1

636 Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives.. **2022**, 227, 152216 0

635 Comparison between an in-house SARS-CoV-2 ELISpot and the T-Spot[®] 'Discovery' SARS-CoV-2 for the assessment of T cell responses in prior SARS-CoV-2-infected individuals.. **2022**, 150-151, 105158

634 Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing.. **2022**, 108, 108767 0

633 Table_1.XLSX. **2020**,

632 Table_2.XLSX. **2020**,

631 Table_3.XLSX. **2020**,

630 DataSheet_1.xlsx. **2020**,

629 DataSheet_2.zip. **2020**,

628 DataSheet_3.zip. **2020**,

627 DataSheet_4.xlsx. **2020**,

626 DataSheet_5.zip. **2020**,

625 Presentation_1.pdf. **2020**,

624 DataSheet_1.pdf. **2020**,

623 Table_1.csv. **2020**,

622 Table_2.csv. **2020**,

621 Table_3.xlsx. **2020**,

620 Table_4.csv. **2020**,

619 DataSheet_1.docx. 2020,

618 DataSheet_1.pdf. 2020,

617 Data_Sheet_1.PDF. 2020,

616 Table_1.DOCX. 2020,

615 DataSheet_1.xls. 2020,

614 DataSheet_2.xls. 2020,

613 Table_1.pdf. 2020,

612 DataSheet_1.pdf. 2020,

611 DataSheet_2.pdf. 2020,

610 Data_Sheet_1.PDF. 2020,

609 Data_Sheet_1.PDF. 2020,

608 Table_1.XLSX. 2020,

607 Table_2.XLSX. 2020,

606 Table_3.XLSX. 2020,

605 Table_4.XLSX. 2020,

604 Table_5.XLSX. 2020,

603 Table_1.docx. 2020,

602 DataSheet_1.docx. 2021,

601 DataSheet_1.pdf. **2020**,

600 DataSheet_1.docx. **2020**,

599 Table_1.xlsx. **2020**,

598 Table_2.xlsx. **2020**,

597 DataSheet_1.pdf. **2020**,

596 DataSheet_1.pdf. **2021**,

595 DataSheet_2.pdf. **2021**,

594 Table_1.xlsx. **2021**,

593 Table_1.docx. **2020**,

592 Data_Sheet_1.pdf. **2020**,

591 Image_1.JPEG. **2020**,

590 Table_1.DOCX. **2020**,

589 Table_2.DOCX. **2020**,

588 Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals.. **2022**, 5, e2210871 2

587 Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination.. **2022**, 1

586 Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. **2022**, 14

585 SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.. **2022**, 17, e0266701 1

584 Eating Disorders in the Time of the Covid-19 Pandemic: A Perspective.. **2022**,

583	Immunity acquired by a minority active fraction of the population could explain COVID-19 spread in Greater Buenos Aires (June-November 2020).. 2022 , 150, e84	
582	Immunological Memory to Common Cold Coronaviruses Assessed Longitudinally Over a Three-Year Period.	
581	Dynamic response landscape of immune cells identified immune dysfunction which predicts disease progression in COVID-19 infected patients.. 2022 , 18, 3066-3081	1
580	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. 2022 , 14, 882	0
579	Features of humoral immunity after COVID-19. 2022 , 24, 337-350	0
578	T HELPER CELL SUBSETS AND THEIR TARGET CELLS IN ACUTE COVID-19.	0
577	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.. 2022 , e0018122	2
576	Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.. 2022 , 13, 869990	1
575	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance.. 2022 , 13, 877101	3
574	High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape.. 2022 , 8, eab15394	0
573	Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. 2022 , 10, 649	1
572	Comparison of the humoral and cellular immunity in COVID-19 convalescents.	0
571	SARS-CoV-2 epitope-specific CD4 + memory T cell responses across COVID-19 disease severity and antibody durability. 2022 ,	2
570	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.. 2022 ,	0
569	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. 2022 , 10, 717	1
568	An efficient immunoassay for the B-cell help function of SARS-CoV-2 specific memory CD4 T cells.. 2022 , 100224	0
567	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. 2022 , 20, e3001609	0
566	TNF- α CD4 T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies.. 2022 , 100640	1

565	Adaptive Immune Responses and Immunity to SARS-CoV-2. 2022 , 13,	3
564	Unraveling T Cell Responses for Long Term Protection of SARS-CoV-2 Infection. 2022 , 13,	0
563	Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.. 2022 , 20, 181	3
562	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. 2022 , 13,	0
561	Inducing broad-based immunity against viruses with pandemic potential.. 2022 , 55, 738-748	0
560	Mucosal immune responses to infection and vaccination in the respiratory tract.. 2022 , 55, 749-780	4
559	The COVID-19 pandemic in the African continent.. 2022 , 20, 167	3
558	Dynamical analysis for the impact of asymptomatic infective and infection delay on disease transmission. 2022 ,	
557	T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.. 2022 ,	4
556	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. 2022 , 13,	1
555	COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.. 2022 , 13, 860238	3
554	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants.. 2022 , eabp8328	5
553	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. 2022 ,	5
552	Design and validation of HIV peptide pools for detection of HIV-specific CD4+ and CD8+ T cells.	
551	SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?. 2022 ,	
550	Myeloid-derived suppressor cells in COVID-19: A review.. 2022 , 238, 109024	1
549	Immunopathology of SARS-CoV-2 Infection: A Focus on T Regulatory and B Cell Responses in Children Compared with Adults. 2022 , 9, 681	0
548	Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products.. 2022 ,	0

547	SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection.. 2022 , 80, 104048	0
546	Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.. 2022 , 11, 100165	1
545	Community-Based Cross-Sectional Study of the Relationship between Sars-Cov-2 Antibody Titres and Clinico-Epidemiological Profile of Population above 6 Years of Age in the Pimpri Chinchwad, Pune, Maharashtra. 2022 ,	
544	SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.. 2022 , 100651	1
543	BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.. 2022 ,	9
542	Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. 2022 , 13,	3
541	A self-pressure-driven blood plasma-separation device for point-of-care diagnostics. 2022 , 123562	0
540	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. 2022 , 80, 104062	2
539	Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved.. 2022 ,	0
538	Diagnosis and treatment of COVID-19 in primary healthcare. 2022 , 28, 1-7	
537	Lung spatial profiling reveals a T cell signature in COPD patients with fatal SARS-CoV-2 infection.	0
536	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?.	
535	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. 2022 , 80, 104073	1
534	Quality Control: Chain Pairing Precision and Monitoring of Cross-Sample Contamination: A Method by the AIRR Community. 2022 , 423-437	
533	Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. 2,	0
532	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T-cell responses. 2022 ,	4
531	Bioinformatic and Experimental Analysis of T Cell Immune Reactivity to SARS-CoV-2 and its Variants. 2022 , 2,	1
530	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022 ,	56.2 14

- 529 Potentiating the cross-reactive IFN- γ cell and polyfunctional T cell responses by heterologous GX-19N DNA booster in mice primed with either a COVID-19 mRNA vaccine or inactivated vaccine.
- 528 CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. **2022**, 17, e0268530 2
- 527 Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview. **2022**, 14, 1082 2
- 526 BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children.
- 525 COH04S1 and Beta Sequence Modified Vaccine Protect Hamsters From SARS-CoV-2 Variants. **2022**, 104457 0
- 524 Gastrointestinal Involvement in SARS-CoV-2 Infection. **2022**, 14, 1188 2
- 523 Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron. **2022**, 14, 1181 0
- 522 Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease. 2
- 521 Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals. **2022**, 13, 2
- 520 Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. **2022**, 13, 0
- 519 Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review. **2022**, 7, 81 3
- 518 A single immunization with cellular vaccine confers dual protection against SARS-CoV -2 and cancer. 0
- 517 Differences in Characteristics of T-Cell Immunity to SARS-CoV-2 in Clinically Healthy Subjects. **2022**, 173, 133-138 1
- 516 Post-COVID-19 Fatigue and SARS-CoV-2 Specific Humoral and T-Cell Responses in Male and Female Outpatients. 13, 0
- 515 Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients. 13, 0
- 514 Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With Influenza and COVID-19. **2022**, 13, 0
- 513 Current vaccine strategies against SARS-CoV-2: Promises and challenges. **2022**, 0
- 512 Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes. **2022**, 20, e3001643 1

511	Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation.	1
510	Absence of negativization of nasal swab test and frailty as risk factors for mortality in elderly COVID-19 patients admitted in long-term care facilities.	
509	Correlates of protection against SARS - CoV -2 infection and COVID-19 disease.	6
508	Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia. 2022 , 13,	
507	Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types. 2022 , 23,	1
506	Mouse models in COVID-19 research: analyzing the adaptive immune response.	1
505	Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?.	3
504	T-cell responses to SARS-CoV-2 in unexposed South African women. 5, 150	0
503	Awareness, perception, and acceptance of coronavirus vaccines by health-care workers approved for restricted emergency use in India: A web-based cross-sectional study. 2022 , 8, 86	
502	Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boule-SEI awards: A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boule Group to honor the Balmis Expedition. 2022 , 3, 136-145	
501	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. 13,	0
500	Preclinical Study of Formulated Recombinant Nucleocapsid protein, the Receptor Binding Domain of the Spike protein, and Truncated Spike (S1) Protein as Vaccine Candidates against COVID-19 in Animal Models. 2022 ,	0
499	Artificial intelligence and clinical data suggest the T cell mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity. 2022 ,	0
498	Lasting SARS-CoV-2'specific IgG'Antibody response in health care workers from Venezuela, 6 months after vaccination with Sputnik V. 2022 ,	0
497	Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2. 12,	0
496	Understanding COVID-19 Vaccines Today: Are T-cells Key Players?. 2022 , 10, 904	0
495	Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19. 2022 , 111020	3
494	Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers. 2022 , 12,	0

- 493 Long-lasting adaptive Immune memory specific to SARS-CoV-2 in convalescent COVID-19 Stable People living with HIV. Publish Ahead of Print, 1
- 492 Traditional Vietnamese medicine Kovir capsule in patients with mild COVID -19: A double-blind randomized controlled trial. 0
- 491 Immune System and Psychological State of Pregnant Women during COVID-19 Pandemic: Are Micronutrients Able to Support Pregnancy?. **2022**, 14, 2534 2
- 490 Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection. 0
- 489 Lung Spatial Profiling Reveals a T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection. **2022**, 11, 1864 0
- 488 Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. **2022**, 2, 275-308 0
- 487 Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. **2022**, 111013 0
- 486 Immune Response to SARS-CoV-2 Vaccines. **2022**, 10, 1464 2
- 485 Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. 3
- 484 An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants. 0
- 483 Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19. **2022**, 12, 2
- 482 Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike. 13, 0
- 481 Measuring SARS-CoV-2 T cell immunity with a scalable qPCR-based assay. 0
- 480 A Bioinformatics Approach to Investigate Structural and Non-Structural Proteins in Human Coronaviruses. 13, 0
- 479 Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. 13, 0
- 478 Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination. **2022**, 13, 2
- 477 Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency. 13, 0
- 476 An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys. 0

475	Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. 2022 , 23, 6394	0
474	Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood. 2022 , 6, 398-407	
473	Immunological memory to SARS-CoV -2 infection and COVID -19 vaccines.	12
472	Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. 13,	0
471	Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic. 2022 , 23, 451-460	1
470	Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual. 2022 , 1, 20220009	1
469	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. 2022 , 21-63	
468	Immunopterin: A prospective therapy and preventative to fight COVID-19?. 2022 , 33, 11-20	
467	Passive Immunotherapeutic Approaches for Treating Covid-19: A Comprehensive Review. 2022 , 11, 52-61	0
466	Antigenic Determinants of SARS-CoV-2-Specific CD4+ T Cell Lines Reveals M Protein-Driven Dysregulation of Interferon Signaling. 13,	1
465	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. 2022 , 13,	1
464	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. 2022 , 10, 1031	0
463	Estimating the effect of non-pharmaceutical interventions on US SARS-CoV-2 infections in the first year of the pandemic. 2022 , 9,	
462	Humoral and T cell immune responses over time following SARS-CoV-2 vaccination. 2022 , 21, 54-60	
461	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. 13,	1
460	The humoral response and antibodies against SARS-CoV-2 infection. 2022 , 23, 1008-1020	2
459	Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors. 2022 , 23, 7155	2
458	Immunodominant MHC-II Restricted Epitopes in Human Apolipoprotein B.	0

- 457 Tissue immunity to SARS-CoV-2: Role in protection and immunopathology. 0
- 456 T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Have a Predominant CD4+ T Helper Response to SARS-CoV-2 Peptides and Numerous Virus-Specific CD4+CD8+ Double-Negative T Cells. **2022**, 23, 7219 1
- 455 SARS-CoV-2 spike and nucleocapsid proteins fail to activate human dendritic cells or $\gamma\delta$ T cells. **2022**, 17, e0271463 0
- 454 Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8+ T Cell Response That Confers Partial Protection Against Infection With *Trypanosoma cruzi*. 12, 0
- 453 Immunodeficiency syndromes differentially impact the functional spectrum of SARS-CoV-2-specific T cells elicited by mRNA vaccination. **2022**, 1 1
- 452 Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease. **2022**, 1, 634-648 0
- 451 SARS-Arena: Sequence and Structure-Guided Selection of Conserved Peptides from SARS-related Coronaviruses for Novel Vaccine Development. 13, 0
- 450 Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. **2022**, 2, 0
- 449 SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma. 13, 0
- 448 Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. 13, 0
- 447 Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. **2022**, 10, 1068 0
- 446 Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. 11, 0
- 445 Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. 0
- 444 CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood. 13, 0
- 443 Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. **2022**, 219, 1 1
- 442 Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. 13, 0
- 441 The Differentiation and Maintenance of SARS-CoV-2-Specific Follicular Helper T Cells. 12, 0
- 440 Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery. **2022**, 100697 1

439	T-cell responses to SARS-CoV-2 in unexposed South African women. 5, 150	1
438	Self-Reported Use of COVID-19 Immunologic Test Results to Inform Decisions About Daily Activities and COVID-19 Vaccination.	
437	Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. 2022 , 81, 104129	2
436	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.	1
435	Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope. <i>Cell</i> , 2022 ,	56.2 5
434	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. 13,	0
433	SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens.	1
432	Understanding Immune Responses to Viruses Do Underlying Th1/Th2 Cell Biases Predict Outcome?. 2022 , 14, 1493	2
431	The SARS-CoV-2 Nucleoprotein Induces Innate Memory in Human Monocytes. 13,	0
430	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. 2022 , 10, 1103	0
429	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. 2022 , 50, 101529	1
428	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. 2022 , 25, 104719	
427	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. 2022 , 51, 101542	1
426	Patients Recovering from Severe COVID-19 Develop a Polyfunctional Antigen-Specific CD4+ T Cell Response. 2022 , 23, 8004	2
425	Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants. 2022 , 10, 1149	1
424	Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.	23
423	Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.	0
422	Post-vaccination T cell immunity to omicron. 13,	1

421	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. 11,	1
420	A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.	6
419	Modern antiviral biomedical cell products and their applications for COVID-19 therapy. 2022 , 21, 19-32	
418	An immunologist's guide to immunosenescence and its treatment.	1
417	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Volume 15, 4013-4027	0
416	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. 2022 , 11, 837	
415	Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination.	0
414	Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?.	0
413	Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria. 2022 , 17, e0271382	0
412	Risk of severe COVID-19 infection among adults with prior exposure to children. 2022 , 119,	0
411	Targeting the YXX Motifs of the SARS Coronaviruses 1 and 2 ORF3a Peptides by In Silico Analysis to Predict Novel Virus-Host Interactions. 2022 , 12, 1052	0
410	Regulatory T Cells Decreased during Recovery from Mild COVID-19. 2022 , 14, 1688	3
409	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. 2022 , 23, 8485	1
408	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. 2022 , 7,	0
407	Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19.	7
406	Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. 2022 ,	0
405	COVID -19 outcomes in children, adolescents and young adults with cancer.	1
404	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. 13,	0

403	Seroprevalence of SARS-CoV-2 in Emergency Department Healthcare Workers at S�rio-Liban� Hospital, Brazil.	
402	SARS-CoV-2-reactive IFN-�producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients. 2022 , 12,	0
401	Molecular Mimicry, Hyperactive Immune System, And SARS-COV-2 Are Three Prerequisites of the Autoimmune Disease Triangle Following COVID-19 Infection. 2022 , 109183	3
400	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection.	0
399	Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human.	
398	SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. 2022 , 111284	1
397	Publication trends of research on COVID-19 and host immune response: A bibliometric analysis. 10,	1
396	Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19. 2022 , 119,	0
395	The immune response as a double-edged sword: the lesson learnt during the COVID -19 pandemic.	0
394	Immunogenicity of a three-dose primary series of mRNA COVID-19 vaccines in patients with lymphoid malignancies.	2
393	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. 13,	0
392	A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.	1
391	Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.	0
390	Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination. 13,	
389	Current Vaccine Platforms in Enhancing T-Cell Response. 2022 , 10, 1367	2
388	The striking mimics between COVID-19 and malaria: A review. 13,	1
387	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. 2022 , 5, e2226335	2
386	RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.	1

- 385 Viral Dynamic Surveillance in COVID-19 Patients: A Cohort Study. **2022**, 2022, 1-10
- 384 Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. **2022**, 159, 116-123
- 383 Immunological evaluation of patients with 2019 novel coronavirus pneumonia: CD4+ and CD16+ cells may predict severity and prognosis. **2022**, 17, e0268712
- 382 Design and validation of HIV peptide pools for detection of HIV-specific CD4+ and CD8+ T cells. **2022**, 17, e0268370
- 381 Where do T cell subsets stand in SARS-CoV-2 infection: an update. 12, 0
- 380 Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the *Saccharomyces cerevisiae* cell surface. 13, 0
- 379 Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination. 1
- 378 Design of a Novel Recombinant Protein Vaccine Based on BA.4 and BA.5 subvariants of SARS-CoV-2: An immunoinformatic and structural approach.
- 377 Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.
- 376 Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. **2022**, 13, 1
- 375 CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques. 3
- 374 NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. 2
- 373 Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. **2022**, 219, 1
- 372 Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice. **2022**, 10, 1305 0
- 371 Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. **2022**, 13, 0
- 370 SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic.. **2022**, 2
- 369 COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. 13, 1
- 368 Emerging trends of research on mRNA vaccines: A co-citation analysis.

- 367 Vaccination in patients with kidney failure: lessons from COVID-19. 2
- 366 Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. **2022**, 3, 100716 2
- 365 Evaluation of Kidney Transplant Patients Infected with COVID-19 in Turkey. **2022**, 32, 283-288
- 364 A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity. 0
- 363 Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people. 1
- 362 Analysis of differences in lymphocyte subsets and CD4+ T cells immune activation between re-detectable positive and non-re-detectable positive COVID-19 convalescent patients.
- 361 COVID-19 and Fungal Infections: A Double Debacle. **2022**, 105039 1
- 360 The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. **2022**, 1
- 359 SARS-CoV-2 specific CD4+ T cell longevity correlates with Th17-like phenotype. **2022**, 104959
- 358 SARS-CoV-2 immunity and vaccine strategies in people with HIV. 0
- 357 A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. **2022**, 153, 113499 0
- 356 Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon- γ release assay. **2022**, 122, 841-849 1
- 355 Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. **2022**, 1868, 166527 0
- 354 Heterogeneity in vaccinal immunity to SARS-CoV-2 can be addressed by a personalized booster strategy. 0
- 353 Regulation of Innate and Adaptive Immunity using Herbal Medicine: Benefits for the COVID-19 Vaccination. Publish Ahead of Print, 0
- 352 What Proportion of Population has achieved Cellular Immunity against SARS-CoV-2 after Booster Vaccination: A Cross-sectional Study. 0
- 351 Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. **2022**, 23, 10679 0
- 350 Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. **2022**, 25, 105105 1

- 349 Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. **2022**, 244, 109103 1
- 348 COVID-19: Vaccines and therapeutics. **2022**, 75, 128987 0
- 347 SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study. **2022**, 16, 100371 0
- 346 Tetramer-Associated T Cell Receptor Sequencing. **2022**, 183-208 0
- 345 Immunoglobulin G and immunoglobulin M positivity in relation to coronavirus disease 2019 severity. **2022**, 35, 378 0
- 344 The immunopathogenesis of SARS -CoV-2 infection in children: diagnostics, treatment and prevention. **2022**, 11, 0
- 343 SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. **2022**, 143-160 0
- 342 High-resolution analysis of individual spike peptide-specific CD4 + T-cell responses in vaccine recipients and COVID -19 patients. **2022**, 11, 0
- 341 T cells in SARS-CoV-2 infection and vaccination. **2022**, 10, 251513552211150 0
- 340 The role of severe acute respiratory syndrome coronavirus 2 viroporins in inflammation. **2022**, 12, 114 0
- 339 COVID-19 in Blood Donors at Laquintinie Hospital in Douala during the Third Wave: A Cross Sectional Study. **2022**, 12, 367-379 0
- 338 Covid-Associated Pernio is the Product of an Abortive Sars-Cov-2 Infection Resulting in the Deposition of Inflammatory Viral Rna and a Local Interferon Response. 0
- 337 From Alpha to omicron: The response of T cells. **2022**, 3, 146-150 2
- 336 Seronegative immunity to SARS-CoV-2: a case study. **2022**, 18, 0
- 335 N protein based vaccine against SARS-CoV-2 produces a strong T cell immune response to N Protein of novel strains. **2022**, 0
- 334 Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2. **2022**, 23, 1324-1329 1
- 333 Leveraging lessons learned from the COVID-19 pandemic for HIV. **2022**, 2, 0
- 332 Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. **2022**, 11, 5103 0

331	Heterogenous CD8+ T Cell Maturation and Polarization in Acute and Convalescent COVID-19 Patients. 2022 , 14, 1906	2
330	Redox stress in COVID-19: Implications for hematologic disorders. 2022 , 101373	0
329	After the virus has cleared can preclinical models be employed for Long COVID research?. 2022 , 18, e1010741	1
328	Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. 2022 , 13,	0
327	Covid-19 Vaccines Immunity, Variants, Boosters. 2022 , 387, 1011-1020	9
326	Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy. 2022 , 104195	0
325	Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. 2022 , 13,	0
324	New insights into human immune memory from SARS-CoV -2 infection and vaccination.	1
323	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. 2022 , 219,	4
322	Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. 13,	0
321	Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above. 1-7	1
320	The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition. 2022 , 13,	3
319	Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2. 2022 , 11, 1035	0
318	A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. 2022 , 13,	4
317	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. 13,	0
316	Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination.	1
315	Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines. 2022 , 10, 1606	0
314	Longitudinal Comparison of Neutralizing Antibody Responses to COVID-19 mRNA Vaccines after Second and Third Doses. 2022 , 10, 1459	0

313	Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19. 13,	0
312	Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19. 2022 , 10,	0
311	Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance. 2022 , 11, 2743	2
310	In Vitro Stimulation with Live SARS-CoV-2 Suggests Th17 Dominance In Virus-Specific CD4+ T Cell Response after COVID-19. 2022 , 10, 1544	0
309	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. 13,	1
308	SARS-CoV-2 antibody response to symptoms indicative of COVID-19 in a non-infected population in Japan: A cross-sectional study. 2022 ,	0
307	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. 2022 , 14,	5
306	Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies. 2022 , 12,	1
305	Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19 2022 , 23,	0
304	Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. 13,	1
303	Translation landscape of SARS-CoV-2 noncanonical subgenomic RNAs. 2022 ,	0
302	Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?. 2022 , 18, e1010821	1
301	Cross-reactivity of SARS-CoV-2 and influenza A specific T cells in individuals exposed to SARS-CoV-2. 2022 , 7,	0
300	COVID-19 immunopathology: From acute diseases to chronic sequelae.	1
299	Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. 2022 , 14,	1
298	SARS-CoV-2 vaccines: A double-edged sword throughout rapid evolution of COVID-19.	0
297	Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. 13,	1
296	SARS-CoV-2-specific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer. 2022 ,	0

295	SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. 2022 , 12,	3
294	Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. 2022 , 11,	4
293	Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development. 2022 , 79,	0
292	Correlation of antigen-specific immune response with disease severity among COVID-19 patients in Bangladesh. 13,	0
291	HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2. 2022 , 5,	0
290	Evaluation of specific T cell immune response to SARS-CoV-2 in COVID-19 infection and following Gam-COVID-Vac vaccine prophylaxis. 2022 , 25, 267-274	0
289	SARS-CoV-2 in immunocompromised individuals. 2022 ,	1
288	The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022. 2022 , 13,	1
287	Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. 13,	0
286	Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.	2
285	A ubiquitous bone marrow reservoir of preexisting SARS-CoV-2-reactive memory CD4+ T lymphocytes in unexposed individuals. 13,	0
284	COVID -19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID -19 pediatric convalescents. 2022 , 33,	0
283	Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2. 2022 , 85, 104294	2
282	Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination. 2022 , 2, 154-158	0
281	Bacterial ligands in the rehabilitation of healthcare workers after COVID-19. 2022 , 32, 716-727	0
280	Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases. 2022 , 12,	0
279	SARS-CoV-2 The Role of Natural Immunity: A Narrative Review. 2022 , 11, 6272	1
278	Simultaneous Identification of Functional Antigen-Specific CD8+ and CD4+ Cells after In Vitro Expansion Using Elongated Peptides. 2022 , 11, 3451	0

277	Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination. 2022 , 10, 1784	0
276	Chilblains outbreak during COVID -19 pandemic: A Type-I interferonopathy?. 2022 , 33,	0
275	Central and effector memory T cells in peripheral blood of patients with interstitial pneumonia: preliminary clues from a COVID-19 study. 2022 , 23,	1
274	Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial. 11,	0
273	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. 2022 ,	0
272	Effector-Memory B-Lymphocytes and Follicular Helper T-Lymphocytes as Central Players in the Immune Response in Vaccinated and Nonvaccinated Populations against SARS-CoV-2. 2022 , 10, 1761	0
271	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. 2022 , 10, 2628	0
270	Adaptive immunity to SARS-CoV-2 infection: A systematic review. 13,	2
269	Cross-Reactive T Cell Response Exists in Chronic Lymphocytic Choriomeningitis Virus Infection upon Pichinde Virus Challenge. 2022 , 14, 2293	0
268	Improved control of SARS-CoV-2 by treatment with nucleocapsid-specific monoclonal antibody.	1
267	Immune system disturbances after a new coronavirus infection COVID-19. 2022 , 14, 26-37	1
266	Humoral and cellular immune responses to CoronaVac up to one year after vaccination. 13,	1
265	Design Strategies for and Stability of mRNA-lipid Nanoparticle COVID-19 Vaccines. 2022 , 14, 4195	2
264	Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. 2022 , 5, e2236397	1
263	Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. 2022 , 17, e0276241	0
262	Indirect Virus Transmission via Fomites Can Counteract Lock-Down Effectiveness. 2022 , 19, 14011	0
261	Insertion/deletion hotspots in the Nsp2, Nsp3, S1, and ORF8 genes of SARS-related coronaviruses. 2022 , 22,	2
260	Influenza Infection in Ferrets with SARS-CoV-2 Infection History.	0

259	Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study. 2022 , 22,	1
258	Stability of SARS-CoV-2 spike antigens against mutations.	0
257	Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.	1
256	The m7G Modification Level and Immune Infiltration Characteristics in Patients with COVID-19. Volume 15, 2461-2472	0
255	Immune response induced by novel coronavirus infection. 12,	1
254	Distorted TCR repertoires define multisystem inflammatory syndrome in children. 2022 , 17, e0274289	0
253	Assessing anti-SARS-CoV-2 cellular immunity in 571 vaccines by using an IFN- γ release assay.	0
252	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. 13,	0
251	Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. 13,	0
250	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. 2022 , 10, 1762	0
249	Immunoinformatics Identification of the Conserved and Cross-Reactive T-Cell Epitopes of SARS-CoV-2 with Human Common Cold Coronaviruses, SARS-CoV, MERS-CoV and Live Attenuated Vaccines Presented by HLA Alleles of Indonesian Population. 2022 , 14, 2328	1
248	Construction and evaluation of a self-replicative RNA vaccine against SARS-CoV-2 using yellow fever virus replicon. 2022 , 17, e0274829	0
247	SARS-CoV-2 infected children form early immune memory responses dominated by nucleocapsid-specific CD8+ T cells and antibodies. 13,	0
246	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. 2022 , 25, 105412	1
245	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.	0
244	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. 2022 , 7,	1
243	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. 2022 ,	0
242	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. 2022 , 25, 105379	3

241	COVID-19. 2023 , 173-273	0
240	II. COVID-19: How Far Has the Pathogenesis been Elucidated?. 2021 , 110, 2355-2360	0
239	Emerging Effects of IL-33 on COVID-19. 2022 , 23, 13656	0
238	Bioinformatics and systems biology approaches to identify molecular targeting mechanism influenced by COVID-19 on heart failure. 13,	0
237	Identification of COVID-19 severity biomarkers based on feature selection on single-cell RNA-Seq data of CD8+ T cells. 13,	0
236	Hydrophobicity identifies false positives and false negatives in peptide-MHC binding. 12,	0
235	A Review on Structural, Non-structural, and Accessory Proteins of SARS-CoV-2: Highlighting Drug Target Sites. 2022 , 152302	0
234	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. 2022 , 10, 1931	0
233	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.	0
232	Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. 2022 , 12,	0
231	Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.	0
230	Interferon- β treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. 2022 , 13,	2
229	Subgenomic RNAs and Their Encoded Proteins Contribute to the Rapid Duplication of SARS-CoV-2 and COVID-19 Progression. 2022 , 12, 1680	0
228	Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. 2022 , 19,	1
227	Parallel analysis of multiple human memory CD4 + T cell subsets within antigen-specific responses using cell proliferation dyes.	0
226	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. 2022 , 7,	0
225	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. 2022 , 113, 109428	4
224	Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity. 2022 , 105643	0

223	Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery.	2
222	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. 13,	0
221	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. 2022, 10, 1948	0
220	Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19. 2023, 246, 109209	1
219	A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. 2023, 324, 199024	1
218	Ad26.COVS priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination. 2023, 26, 105753	0
217	Unaltered T cell responses to common antigens in individuals with Parkinson's disease. 2023, 444, 120510	0
216	Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. 2023, 127, 11-16	0
215	Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice. 2022, 10,	0
214	High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. 2022, 13,	0
213	Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. 2022, 42,	0
212	SARS-CoV-2 epitopes inform future vaccination strategies. 13,	0
211	SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. 11,	1
210	Current understanding of T cell immunity against SARS-CoV-2. 2022, 42,	1
209	Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. 2022, 14, 2584	0
208	Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity.	0
207	Engagement of the G3BP2-TRIM25 Interaction by Nucleocapsid Protein Suppresses the Type I Interferon Response in SARS-CoV-2-Infected Cells. 2022, 10, 2042	0
206	Early CD4+ T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory. 2022, 12,	0

- 205 Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. **2022**, 23, 15027 1
- 204 Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions. **2022**, 2, 0
- 203 BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children. **2022**, 7, 0
- 202 The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age. 13, 0
- 201 Inhalable SARS-CoV-2 vaccines for single-dose dry-powder aerosol immunization and orchestrated mucosal/systemic immune responses. 0
- 200 Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients. **2022**, 10, 2117 0
- 199 Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV. 13, 0
- 198 Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine, in non-human primates. 0
- 197 Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. 2
- 196 Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine. **2022**, 19, 0
- 195 Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human. **2022**, 19, 0
- 194 The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. 1
- 193 Impaired CD4+ T cell recognition of SARS-CoV-2 variants of concern. **2022**, 23, 1671-1672 0
- 192 Donor selection for adoptive cell therapy with CD45RA^{hi} memory T cells for COVID-19 patients, and dexamethasone and interleukin-15 effect on the phenotype, proliferation and interferon gamma release. **2022**, 0
- 191 A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave. 9, 0
- 190 COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. **2022**, 8, 0
- 189 Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. **2022**, 30, 1662-1670.e4 1
- 188 Activation induced marker (AIM) assays for identification of T. cruzi -specific CD4 or CD8 T cells in chronic Chagas disease patients. 0

- 187 Genetic and Structural Data on the SARS-CoV-2 Omicron BQ.1 Variant Reveal Its Low Potential for Epidemiological Expansion. **2022**, 23, 15264 4
- 186 Can vitamin D status influence seroconversion to SARS-COV2 vaccines?. 13, 0
- 185 Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. **2022**, 10, 2167 0
- 184 Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. **2022**, 10, 2180 0
- 183 Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. **2022**, 23, 15122 0
- 182 Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections. 0
- 181 The risk of COVID-19 can be predicted by a nomogram based on m6A-related genes. **2022**, 106, 105389 0
- 180 High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. 13, 0
- 179 Age-associated remodeling of T cell immunity and metabolism. **2022**, 0
- 178 Regulation and the Normativity Problem. 1-17 0
- 177 Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response. **2022**, 5, 0
- 176 Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID -19 vaccination: A reactive lymphomatoid papulosis-like eruption and a bona fide lymphoma. 0
- 175 Impact of SARS-CoV-2 exposure history on the T cell and IgG response. **2022**, 100898 0
- 174 Dressing bacteria with a hybrid immunoactive nanosurface to elicit dual anticancer and antiviral immunity. 2210949 0
- 173 Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. **2022**, 105862 1
- 172 Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older. **2022**, 0
- 171 Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. **2023**, 95, 0
- 170 The correlation between serum 25-hydroxy-vitamin D levels and anti-SARS-CoV-2 S-RBD IgG and neutralizing antibody levels among cancer patients receiving COVID-19 vaccines. 9, 0

169	Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. 2022 , 10, 2132	2
168	Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19. 2022 , 13,	0
167	Differential peripheral blood mononuclear cell reactivity against SARS-CoV-2 proteins in naïve and previously infected subjects following COVID-19 vaccination. 2022 , 2, 172-176	1
166	Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). 2023 , 13,	0
165	The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.	0
164	Clinical Features of COVID-19 and Differentiation from Other Causes of CAP. 2023 , 44, 008-020	0
163	Assessment of Immunogenic and Antigenic Properties of Recombinant Nucleocapsid Proteins of Five SARS-CoV-2 Variants in a Mouse Model. 2023 , 15, 230	0
162	Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study. 9,	0
161	Ready and waiting to go. 12,	0
160	Structural Analysis and Epitope Prediction of S2 Domain of SARS-CoV-2, Conservation Analysis Among Major Variants.	0
159	Analysis of Antigen-Specific T and B Cells for Monitoring Immune Protection Against SARS-CoV-2. 2023 , 3,	0
158	Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients. 13,	0
157	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. 2023 , 15, 175	5
156	Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults. 2023 , 20,	0
155	Sequence similarity between SARS-CoV-2 nucleocapsid and multiple sclerosis-associated proteins provides insight into viral neuropathogenesis following infection. 2023 , 13,	0
154	COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults. 2023 , 12, 488	1
153	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review.	0
152	Ancestral origins are associated with SARS-CoV-2 susceptibility and protection in a Florida patient population. 2023 , 18, e0276700	0

- 151 An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. **2023**, 26, 105904 ○
- 150 Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. **2023**, 11, 101 4
- 149 Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose. Publish Ahead of Print, ○
- 148 Diagnostic performance of lateral flow immunoassays for COVID-19 antibodies in Peruvian population. ○
- 147 A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants. **2023**, ○
- 146 Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. **2023**, ○
- 145 Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. **2023**, 133, ○
- 144 Targets and cross-reactivity of human T cell recognition of Common Cold Coronaviruses. ○
- 143 Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. **2023**, 315, 121374 ○
- 142 Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. **2023**, 128, 112-120 ○
- 141 Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination. **2022**, 209, 1892-1905 1
- 140 On the Evolutionary Trajectory of SARS-CoV-2: Host Immunity as a Driver of Adaptation in RNA Viruses. **2023**, 15, 70 ○
- 139 T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. **2022**, 28, 211-222 ○
- 138 Iron Deficiency Anemia and COVID-19. **2022**, 10, 157-162 ○
- 137 Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. ○
- 136 Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant. **2022**, 209, 2104-2113 1
- 135 Immunogenetic Predisposition to SARS-CoV-2 Infection. **2023**, 12, 37 ○
- 134 A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants. ○

- 133 Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. **2023**, 11, 58 ○
- 132 The Cold-Adapted, Temperature-Sensitive SARS-CoV-2 Strain TS11 Is Attenuated in Syrian Hamsters and a Candidate Attenuated Vaccine. **2023**, 15, 95 ○
- 131 Effect of physical activity on COVID-19 and underlying mechanisms. 2, ○
- 130 The role of T cell immunity in COVID-19. **2023**, 129-140 ○
- 129 Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. ○
- 128 miRNAomics in COVID-19. **2023**, 145-160 ○
- 127 A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19). **2023**, 11, 295 ○
- 126 Staining of activated α -integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4+ and CD8+ T cells. 13, ○
- 125 Positive-strand RNA viruses—Keystone Symposia report. ○
- 124 Immunological and metabolic characteristics of the Omicron variants infection. **2023**, 8, 1
- 123 Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. **2023**, 237-262 ○
- 122 Computational approaches in COVID-19 vaccine development. **2023**, 339-350 ○
- 121 Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. **2023**, 10, 148 ○
- 120 Machine learning identifies T cell receptor repertoire signatures associated with COVID-19 severity. **2023**, 6, ○
- 119 Applications of multiomics data in COVID-19. **2023**, 351-365 ○
- 118 Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion. 14, ○
- 117 The COVID-19 pandemic in sub-Saharan Africa: The significance of presumed immune sufficiency. **2023**, 12, ○
- 116 Viral immunity: Basic mechanisms and therapeutic applications—Keystone Symposia report. ○

- 115 Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress. **2023**, 11, 218 ○
- 114 CoV2-TCR: A web server for screening TCR CDR3 from TCR immune repertoire of COVID-19 patients and their recognized SARS-CoV-2 epitopes. **2023**, 21, 1362-1371 ○
- 113 Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. ○
- 112 Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection. **2023**, 19, e1011128 ○
- 111 Host Recovery from Respiratory Viral Infection. **2023**, 41, ○
- 110 Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs. **2023**, 3, 6-13 ○
- 109 State of the art in epitope mapping and opportunities in COVID-19. **2023**, 9, ○
- 108 Quantitative analysis of high-throughput biological data. ○
- 107 Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern. **2023**, 8, ○
- 106 Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFN γ -releasing cells: An exploratory study. **2023**, 18, e0281444 1
- 105 T-cell activation-induced marker assays in health and disease. ○
- 104 Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters. 14, ○
- 103 Regarding: Evaluation of SARS-CoV-2 antibody levels on hospital admission as a correlate of protection against mortality. ○
- 102 Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. **2023**, 8, ○
- 101 Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. **2023**, 11, 806 1
- 100 Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. **2023**, 20, ○
- 99 Structural insights into protection against a SARS-CoV-2 spike variant by T cell receptor diversity. **2023**, 299, 103035 ○
- 98 Immunization of MERS-CoV-2-infected mice with a sublethal dose of MERS-CoV or VRP-MERS-S. **2023**, 4, 102171 ○

97	Dendrobium officinale aqueous extract influences the immune response following vaccination against SARS-CoV-2. 2023 , 162, 114702	0
96	Immunological aspects of coronavirus disease caused by SARS-CoV-2. 2020 , 15, 14-21	0
95	Defending against SARS-CoV-2: The T cell perspective. 14,	0
94	Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. 2023 , 28, 100600	0
93	Analysis of Humoral and Cellular Immunity after SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Immunomodulatory Drugs.	0
92	An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines. 2023 , 112, 1345-1350	0
91	Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan. 2023 , 13,	0
90	Severely ill and high-risk COVID-19 patients exhibit increased peripheral circulation of CD62L+ and perforin+ T cells. 14,	0
89	SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. 2023 , 12, 244	1
88	Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors.	0
87	Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. 2023 , 67, 527-537	0
86	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T´cell profile. 2023 , 4, 100955	0
85	Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa. 3,	0
84	T Cell Responses to SARS-CoV-2. 2023 , 41,	1
83	Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization. 2023 , 97,	0
82	Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination. 14,	0
81	Viral Mitigation: Weak Theoretical Underpinnings. 2023 , 9-58	0
80	Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice. 2023 , 11, 429	0

- 79 Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms. **2023**, 11, 408 2
- 78 Employing T-Cell Memory to Effectively Target SARS-CoV-2. **2023**, 12, 301 0
- 77 A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine. **2023**, 19, 0
- 76 T Cell Response to SARS-CoV-2 Coinfection and Comorbidities. **2023**, 12, 321 1
- 75 Integration of serum metabolomics and network pharmacology reveals the immunoenhancing mechanisms of Qishenbuqi capsules. 0
- 74 The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. **2023**, 12, 329 0
- 73 Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice. **2023**, 95, 0
- 72 The Role of Interferons in Long Covid Infection. **2023**, 43, 65-76 0
- 71 Lung T cell response in COVID-19. 14, 0
- 70 Anti-inflammatory SARS-CoV-2 T cell immunity in asymptomatic seronegative Kenyan adults. 0
- 69 Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. **2023**, 26, 106256 0
- 68 Evaluation of QuantiFERON SARS-CoV-2 interferon- γ release assay following SARS-CoV-2 infection and vaccination. 0
- 67 Can T Cells Abort SARS-CoV-2 and Other Viral Infections?. **2023**, 24, 4371 0
- 66 Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. **2023**, 24, 4398 0
- 65 Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. **2023**, 11, 524 0
- 64 Intragenomic rearrangements involving 5'-untranslated region segments in SARS-CoV-2, other betacoronaviruses, and alphacoronaviruses. **2023**, 20, 0
- 63 An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: Application to SARS-CoV-2 immune individuals. **2023**, 515, 113443 0
- 62 Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. **2023**, 11, 545 0

61	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. 2023 , 11, 548	0
60	A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern. 2023 , 11,	0
59	Association of COVID-19 with Comorbidities: An Update. 2023 , 6, 334-354	0
58	Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination. 2023 , 15, 627	1
57	The clinical and epidemiological characteristics of a series of patients living with HIV admitted for COVID-19 in a district hospital. 2023 , 23,	0
56	COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response.	0
55	Seroconversion in COVID-19 Infection and Comparison of Antibody Responses in Symptomatic Versus Asymptomatic Individuals. 2023 , 17, 590-596	0
54	Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. 2023 , 95,	1
53	Correlation of Lymphocyte Subpopulations, Clinical Features and Inflammatory Markers during Severe COVID-19 Onset. 2023 , 12, 414	1
52	Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. 14,	0
51	Pharmacological potential of <i>Withania somnifera</i> (L.) Dunal and <i>Tinospora cordifolia</i> (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. 14,	0
50	Short- and long-term T cell and antibody responses following Dexamethasone treatment in COVID-19.	0
49	Immunogen-Specific Strengths and Limitations of the Activation-Induced Marker Assay for Assessing Murine Antigen-Specific CD4+ T Cell Responses. 2023 , 210, 916-925	0
48	Differential regulatory T cell signature after recovery from mild COVID-19. 14,	0
47	Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines. 2023 , 95,	1
46	SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. 14,	0
45	An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial. 14,	0
44	Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. 2023 , 156, 111-126	0

- 43 Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. **2023**, 3, 418-435 ○
- 42 A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses. **2023**, 3, ○
- 41 Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. **2023**, 8, ○
- 40 Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients. **2023**, ○
- 39 Architecture of the SARS-CoV-2-specific T cell repertoire. 14, ○
- 38 Potency assessment of IFN γ -producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects. **2023**, 6, e202201759 ○
- 37 Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. 14, ○
- 36 SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. **2023**, ○
- 35 Th-1, Th-2, Th-9, Th-17, Th-22 type cytokine concentrations of critical COVID-19 patients after treatment with Remdesivir. **2023**, 228, 152378 ○
- 34 Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. 14, ○
- 33 A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults. **2023**, 11, 723 ○
- 32 Robust SARS-CoV-2 T cell responses with common TCR motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. **2023**, 4, 101017 ○
- 31 Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection. 11, ○
- 30 Virus-Specific Stem Cell Memory CD8+ T Cells May Indicate a Long-Term Protection against Evolving SARS-CoV-2. **2023**, 13, 1280 ○
- 29 Tracking of activated cTfh cells following sequential influenza vaccinations reveals transcriptional profile of clonotypes driving a vaccine-induced immune response. 14, ○
- 28 Pre-clinical models to define correlates of protection for SARS-CoV-2. 14, ○
- 27 Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity. **2023**, 115948 ○
- 26 At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. **2023**, 28, ○

- 25 HLA Variation and SARS-CoV-2 Specific Antibody Response. **2023**, 15, 906 ○
- 24 Assessing the generation of tissue resident memory T cells by vaccines. ○
- 23 Multisystem Inflammatory Syndrome in Children (MIS-C). ○
- 22 The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA). **2023**, ○
- 21 High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. **2023**, 18, e0283983 ○
- 20 Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. **2023**, 14, ○
- 19 Immunology of COVID-19. **2024**, 52-71 ○
- 18 Metabolic dysregulation impairs lymphocyte function during severe SARS-CoV-2 infection. **2023**, 6, ○
- 17 Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and $\gamma\delta$ T cell perturbations. **2023**, 8, ○
- 16 Vitamin D and SARS-CoV-2. ○
- 15 Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. 14, ○
- 14 An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. **2023**, 14, ○
- 13 Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma. ○
- 12 The effect of Pickering emulsion adjuvants on the immune efficacy of the COVID-19 polypeptide vaccine. **2023**, ○
- 11 Antigen-specificity measurements are the key to understanding T cell responses. 14, ○
- 10 SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. **2023**, 11, 849 ○
- 9 Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. 14, ○
- 8 Features of the Immune Response in COVID-19. **2023**, 12, 122-129 ○

- 7 Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. **2023**, 3, ○
- 6 Immune interference in effectiveness of influenza and COVID-19 vaccination. 14, ○
- 5 Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems. **2023**, 105448 ○
- 4 Associations of clinical features and dynamic immune response with the duration of viral RNA shedding in patients with COVID-19. **2023**, 2, e9130015 ○
- 3 Memory SARS-CoV-2 T-cell response in convalescent COVID-19 patients with undetectable specific IgG antibodies: a comparative study. 14, ○
- 2 The unreversible reduced but persistent activated NK and CD8+ T cells in severe/critical COVID-19 during omicron pandemic in China. **2023**, 12, ○
- 1 A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2. **2023**, 4, ○